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Resumen y Abstract  IX 
 
Resumen 
Pregunta de investigación: en este trabajo se evaluó la efectividad y la seguridad del 
tratamiento endovascular (i.e. infusión intraarterial de vasodilatador, angioplastia con 
balón, stent recuperable o terapia combinada) en comparación con el tratamiento estándar 
para el manejo del vasoespasmo cerebral en adultos con hemorragia subaracnoidea 
aneurismática. 
Antecedentes: aunque el 30% de los pacientes con vasoespasmo cerebral desarrollan 
isquemia cerebral tardía, actualmente no hay forma de saber que pacientes desarrollarán 
esta complicación. Existe una amplia gama de opciones terapéuticas y la elección se basa 
en la experiencia clínica, las preferencias del paciente y los eventos adversos. 
Características de los estudios: se realizó búsqueda sistemática de estudios 
controlados hasta el 2 de mayo de 2020. Se incluyó 26 estudios con 1783 pacientes. Los 
estudios incluyeron hombres y mujeres mayores de 18 años con diagnóstico clínico y 
radiológico de hemorragia subaracnoidea aneurismática y vasoespasmo cerebral. Diez 
estudios (799 pacientes) incluyeron pacientes que recibieron terapia endovascular versus 
tratamiento médico. La mayoría de los estudios utilizó infusión intraarterial de 
vasodilatador (i.e. papaverina, nimodipino, nicardipino, colforsina, etc.). Quince estudios 
(912 pacientes) compararon diferentes modalidades de terapia endovascular entre sí. Un 
estudio (72 pacientes) incluyó tres brazos de comparación (terapia médica, vasodilatador 
intraarterial y angioplastia con balón). 
Resultados clave: el estado funcional a largo plazo y la mejoría angiográfica sugiere ser 
superior con vasodilatador intraarterial comparado con tratamiento médico (riesgo de 
sesgo moderado / serio). No se observó diferencias significativas en los eventos adversos 
entre la terapia endovascular versus el tratamiento médico (riesgo de sesgo moderado / 
serio). 
Calidad de la evidencia: los resultados deben interpretarse con cautela: riesgo de sesgo, 
imprecisión, inconsistencia y heterogeneidad. 
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Review question: in this review we assessed the effectiveness and safety of endovascular 
therapy (i.e. intra-arterial vasodilator infusion, balloon angioplasty, stent or combined 
therapy) compared to standard management for treatment of cerebral vasospasm in adults 
with aneurysmal subarachnoid haemorrhage. 
Background: although 30% of patients with cerebral vasospasm develop delayed cerebral 
ischaemia, currently there is no way to know whether a patient would have this 
complication. There are a wide range of treatment options and the choice is based on the 
experience of the clinicians, patient preferences and adverse effects. 
Trial characteristics: we searched the available literature up to 2 May 2020 and included 
26 controlled studies with 1783 patients. The studies included both men and women aged 
over 18 years with clinical diagnosis and radiological diagnosis of aneurysmal 
subarachnoid haemorrhage and cerebral vasospasm. Ten studies (799 patients) included 
people that had been treated with endovascular treatment and compared with medical 
therapy. In most studies, people received intra-arterial vasodilatory infusion (i.e. 
papaverine, nimodipine, nicardipine, colforsin). Fifteen studies compared endovascular 
therapy against each other technique (912 participants). One study (72 patients) included 
three arms (medical therapy, intra-arterial vasodilator infusion and balloon angioplasty). 
Key results: long-term functional status and angiographic improvement suggest 
superiority with intra-arterial vasodilator compared to medical treatment (moderate / serous 
risk of bias). We found no difference on adverse events rate between endovascular therapy 
and medical treatment (moderate / serous risk of bias). 
Quality of evidence: results should be interpreted with cautio because the risk of bias, 
imprecision, inconsistency and heterogeneity. 
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1.1 Description of the condition 
Subarachnoid haemorrhage (SAH) is a medical emergency consisting of bleeding into the 
subarachnoid space and — in some cases — the parenchyma or ventricular space, or both 
(1). Sometimes this bleeding is caused by trauma, however it is usually caused by the 
rupture of a brain aneurysm, and is a major cause of haemorrhagic stroke (2).  
 
Worldwide, aneurysmal SAH occurs in nearly 600,000 people per year(3). Its incidence 
varies by geographic region: for example, it has been reported that Kuwait and Japan have 
an annual incidence of 1.4 and 24.8 cases per 100,000 people/ year, respectively, which 
suggests that aneurysmal SAH may have a genetic component (4). The condition is more 
frequent in women (the ratio of women to men is 1.3:1), and the risk of developing it 
increases with age, with the average age of onset being 50 years (5,6). 
 
The mortality rate of aneurysmal SAH is high; however, in high- income countries it 
decreased from 55% in 1978 to 35% in 2006; this has been partly attributed to the 
development of better health systems, as well as progress made in intensive care 
treatments (3,7). The burden of haemorrhagic stroke resulting from aneurysmal SAH is 
higher than the burden of ischaemic stroke, because it affects a younger age group with 
longer life expectancy (3). 
 
Brain damage resulting from a ruptured intracranial aneurysm occurs in two stages. The 
first phase is a transient cerebral ischaemia caused by a sudden increase of intracranial 
pressure that alters perfusion, while the second is associated with an uncontrolled systemic 
response that affects multiple organs (3). Complications of aneurysmal SAH include 
cerebral vasospasm, hydrocephalus, and re-bleeding. Cerebral vasospasm is a 
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phenomenon defined as the reversible narrowing of the intracranial vessels; it usually 
occurs between four and 14 days after aneurysmal SAH takes place. Up to 90% of patients 
with aneurysmal SAH develop cerebral vasospasm, which may lead to cerebral ischaemia 
in 10% to 45% of cases (8,9). 
 
Cerebral vasospasm can be detected using transcranial Doppler (TCD), computed 
tomography (CT), or digital subtraction angiography (DSA). Some clinical practice 
guidelines recommend performing a CT angiography or a brain perfusion image (or both) 
for its detection, despite the risks associated with using ionising radiation in these patients 
(10). In a meta-analysis that included 17 studies, TCD was recommended due to its 
predictive capability and versatility (11). However, DSA continues to be the gold standard 
for the diagnosis of this condition; it also allows immediate endovascular treatment (10). CT 
multimodality techniques for detecting cerebral vasospasm include computed tomography 
angiography (CTA) and computed tomography perfusion (CTP) imaging. CTA is a fast, non-
invasive, and accurate imaging test performed to identify brain vessels narrowing. Likewise, 
CTP aids in the evaluation of tissue perfusion, for it can help predict cases in which patients 
require further treatment due to the presence of a prolonged mean transit time (12,13). 
 
Prophylaxis for patients with cerebral vasospasm as a result of aneurysmal SAH has been 
attempted. For example, oral nimodipine has been proven to be an effective neuroprotector. 
Other pharmacological therapies that have been tested for treating this condition include 
fasudil, corticosteroids, magnesium sulphate, and others; however, none of these 
treatments has shown clinical significance (10). Additionally, a randomised trial of 
endovascular prophylaxis through balloon angioplasty for preventing cerebral vasospasm 
reported no clear benefit of this therapy (14). Intra-arterial vasodilator infusion (IAVI) is 
another prophylactic strategy for this condition, however there are no studies assessing its 
use.  
 
Treatment of cerebral vasospasm includes one or more of the following: pharmacological 
management, percutaneous transluminal balloon angioplasty (TBA) and IAVI. Although 
endovascular treatment is controversial, it is used for the management of patients in which 
other medical treatments have failed, and those at high risk of developing ischaemia 
according to the Lindegaard ratio (i.e. mean middle cerebral artery flow velocity divided by 
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mean ipsilateral extracranial internal carotid artery flow velocity), which is obtained through 
transcranial Doppler (15). 
1.2  Description of the intervention 
At present, there are three different types of endovascular treatment for cerebral 
vasospasm: 1) IAVI, 2) percutaneous transluminal balloon angioplasty (TBA), and 3) 
retrievable self- expandable stents (10). 
 
Intra-arterial vasodilator infusion is performed under general anaesthesia or conscious 
sedation. After obtaining vascular access, a catheter is inserted in the affected area; then 
a vasodilator agent (e.g. papaverine, milrinone, or calcium channel blockers including 
verapamil, nicardipine, and nimodipine) is administered through the catheter. The 
continuous infusion may last a few minutes and can be repeated several times during the 
same procedure; in addition, this procedure can be performed again in case of recurrence 
(15). IAVI is indicated for the management of a diffuse cerebral vasospasm affecting distal 
blood vessels, since it makes it possible to treat multiple cerebral vascular territories at the 
same time. 
 
On the other hand, TBA consists of mechanical vasodilation using compliant or non-
compliant balloon catheters that are inflated at the affected site for a few seconds. Like 
IAVI, it is performed under general anaesthesia or conscious sedation and after peripheral 
vascular access is achieved. Its use is limited to proximal blood vessels (i.e. the intracranial 
internal carotid artery, proximal anterior cerebral artery (A1 or A2 segment), proximal stem 
of the middle cerebral artery (M1 or M2), and vertebrobasilar territory), and focal cerebral 
vasospasm (16). To give an example, a super-selective endovascular approach through a 
non- compliant balloon catheter was effective in treating patients with focal cerebral 
vasospasm affecting the M1 segment of the middle cerebral artery (16). 
 
The use of retrievable self-expandable stents is a recent endovascular technique still in 
development for this condition. Bhogal has reported a low morbidity rate and a vasodilation 
effect duration greater than 24 hours using this technique (17). 
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1.3 How the intervention might work 
1.3.1 Pharmacological interventions 
One of the objectives of cerebral vasospasm treatment is to achieve vasodilation of brain 
blood vessels by relaxing the vascular smooth muscle of artery walls. Smooth muscle 
contraction requires calcium in the intracellular compartment to form a complex with 
calmodulin that allows the activation of the myosin light-chain kinase (MLCK) enzyme. 
Nevertheless, calcium channel blockers (i.e. nimodipine, nicardipine, and verapamil) 
reduce calcium input into the cell through L-type calcium channels, inhibiting muscle 
contraction. MLCK also inhibits muscle contraction, as it is inhibited directly by fasudil, 
which, in turn, is a rho-kinase inhibitor that promotes vasodilatation by this route (18). 
 
Muscle contraction is also inhibited by increased concentration of cyclic adenosine 
monophosphate (cAMP). Milrinone, papaverine, and colforsin increase intracellular cAMP 
levels by inhibiting phosphodiesterases selectively (milrinone), non- selectively 
(papaverine), or by acting as a direct activator of adenylate cyclase (colforsin) (18). 
 
Regarding the safety of vasodilators for treating cerebral vasospasm, a study on the 
complications associated with intra-arterial administration of nimodipine in patients with this 
condition described that 3% of these patients had new cerebral infarcts secondary to 
thromboembolic events (19). Other complications related to continuous IAVI therapy 
include anticoagulant-associated intracranial haemorrhage, severe hypotension episodes, 
and infection (20). 
1.3.2 Mechanical interventions 
The internal diameter of affected vessels may change when using intraluminal devices, 
such as intraluminal balloons or stents. Balloon catheters can be compliant and non-
compliant, depending on the capacity to change their diameter according to the insufflation 
pressure. When using both types there is a risk of causing arterial dissection or the rupture 
of the blood vessel: with compliant balloons, this is due to the lack of regulation of the final 
diameter, which leads to rupture of the vessel by overdistension; and with non-compliant 
balloons, it is due to their high radial force (21). 
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Few cases of arterial dissection or embolic occlusion have been reported with the use of 
TBA (22). Furthermore, a randomised controlled trial assessing the efficacy and safety of 
prophylactic TBA described a 5% complication rate associated with this procedure, 
consisting of arterial perforation caused by the guidewire and arterial rupture during balloon 
inflation (14). 
1.4 Why it is important to do this review 
The importance of identifying effective treatments for cerebral vasospasm secondary to 
aneurysmal SAH lies in the consequences derived from the care needs of these patients. 
In this sense, one key aspect is the burden of this disease, since the economic burden is 
30% higher when treating people with cerebral vasospasm compared to the management 
of patients without this condition (23). Furthermore, cerebral vasospasm is associated with 
a longer hospital stay (up to 25% longer) and with a higher frequency of readmission within 
12 weeks following the initial hospital discharge (24). According to Macdonald, this might 
explain why only a small proportion of patients with severe cerebral vasospasm (10%) are 
completely independent after 12 weeks of hospitalisation, in comparison to those without 
cerebral vasospasm secondary to aneurysmal SAH (49%) (24). 
 
Currently, there is no consensus on endovascular management of cerebral vasospasm in 
patients with aneurysmal SAH. In fact, studies evaluating the efficacy and safety of medical 
and endovascular therapies for this condition describe mixed outcomes; some state that 
these therapies offer some benefits (25,26); while others report no benefits at all (27,28). 
For example, the reported efficacy of IAVI varies significantly in several studies. A meta-
analysis of 44 studies on IAVI for treating cerebral vasospasm found that angiographic 
improvement was achieved in 33% to 100% of patients, and neurological response 
improvement was observed in 12% to 100% of patients (29). The quality of evidence 
provided in these studies also needs to be assessed. 
 
This review aims to synthesize the findings from the studies on this topic, and assess the 
quality of the evidence they provide. The results will be relevant to decision-makers and the 







The aim of this investigation was to evaluate the efficacy and safety of endovascular 
treatment compared to standard treatment for cerebral vasospasm in patients with 
aneurysmal subarachnoid haemorrhage. 
2.1 Criteria for considering studies for this 
review 
2.1.1 Types of studies 
We included published and unpublished randomised controlled trials and non-randomised 
controlled trials, irrespective of their language. 
2.1.2 Types of participants 
Adults (over 18 years of age) with aneurysmal subarachnoid haemorrhage (SAH), who had 
a previous aneurysm secured through coiling or clipping, and who subsequently developed 
cerebral vasospasm. 
 
Patients were defined as having SAH if they have symptoms compatible with this condition, 
along with intracranial bleeding confirmed by means of computed tomography (CT), 
magnetic resonance imaging (MRI), or the detection of xanthochromia in the cerebrospinal 
fluid. Likewise, the presence of the aneurysm must have been confirmed through digital 
subtraction angiography (DSA), computed tomography angiography (CTA) or magnetic 
resonance angiography (MRA). 
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Cerebral vasospasm was defined according to the following criteria (30,31): 
 
§ Angiographic evidence of cerebral vasospasm, detected by DSA, CTA, or MRA. 
Cerebral vasospasm was considered to be present within the fourth and 21st day after 
the occurrence of aneurysmal SAH, when the angiogram shows focal or generalised 
narrowing of cerebral arteries (as reported by each trialist). 
§ Neurological deterioration associated with radiological cerebral vasospasm that is not 
explained by other causes (i.e. not caused by seizures, hydrocephalus, metabolic 
disorders, re-bleeding, or aneurysm occlusion procedures). Neurological deficit 
includes aphasia, hemiparesis, apraxia, neglect, and decreased level of consciousness. 
§ We also considered studies including patients with rapid and severe increased blood 
flow velocities, obtained through transcranial Doppler (TCD). 
§ No evidence, based on CT or MRI studies, of new cerebral infarction as a result of the 
procedure performed to treat the aneurysm. 
 
As the definition of cerebral vasospasm varies among studies, we also accepted the 
definitions used by each author or group of authors if these are appropriately described. 
2.1.3 Types of interventions 
We included trials comparing endovascular treatment plus standard care versus standard 
care alone. Endovascular therapies may have included the following interventions. 
 
§ Intra-arterial vasodilator infusion (IAVI). We included any vasodilator drug used, 
regardless of the dose or administration protocol, if it is properly described (i.e. one 
single session, repetitive sessions, or continuous infusion through microcatheters). 
§ Percutaneous transluminal balloon angioplasty (TBA), regardless of the number of 
sessions. 
§ Retrievable self-expandable stents. 
 
The indication for treatment of cerebral vasospasm had to be clearly described in each 
study (i.e. parameters considered for the indication of the intervention and how frequently 
it was measured). The indication could be based on the severity or progression of the 
condition (i.e. TCD indices and the degree of the narrowing of the blood vessels observed 
Chapter 2 11 
 
in the CTA or the DSA). In patients with a confirmed diagnosis, indication for treatment 
includes neurological deterioration or changes in multimodality neuromonitoring 
parameters (e.g. continuous electroencephalography, brain tissue oxygen monitoring, 
cerebral microdialysis, etc.) 
2.1.4 Types of outcome measures 
Primary outcome 
Long-term unfavourable outcome after three months of follow-up — defined as 
death, vegetative state, or severe disability — as assessed either with the Glasgow 
Outcome Scale (GOS), modified Rankin Scale (mRS), or Glasgow Outcome Scale 
Extended (GOS-E) (see Appendix 1). 
 
Secondary outcomes 
§ Death from any cause during the follow-up. 
§ Short-term unfavourable outcome (within six months after the aneurysmal SAH): death, 
vegetative state, or severe disability, as assessed either with the GOS, mRS, or GOS-
E. 
§ Cerebral infarction: CT or MRI detection of cerebral infarction within six weeks of 
aneurysmal SAH, not evidenced on early CT/MRI scan (24 to 48 hours after occlusion 
of aneurysm) and not explained by causes other than cerebral vasospasm (e.g. 
ventricular catheter, intraparenchymal hematoma, etc.) 
§ Treatment complications: any serious adverse event associated with the drug or 
procedure used within 24 hours after performing the intervention to treat cerebral 
vasospasm. 
§ Angiographic improvement of cerebral vasospasm. 
§ Procedure-related costs  
§ Length of hospital stay  
§ Quality of life assessed using a validated scale at the end of follow-up. 
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2.2 Search methods for identification of 
studies 
We searched for trials in all languages and arrange for the translation of relevant articles 
where necessary.  
2.2.1 Electronic searches 
We searched the following electronic databases: 
§ MEDLINE (from 1948) (Appendix 2) 
§ Embase (from 1980) (Appendix 2) 
 
We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group 
Information Specialist (Appendix 2) and adapted it for the other database. 
2.2.2 Searching other resources 
We screened the reference lists of included studies and relevant reviews to identify further 
studies for potential inclusion in the review. Also, we contacted authors for missing 
information. 
2.3 Data collection and analysis  
2.3.1 Selection of studies 
Two review authors (LCSD and FNE) independently screened the titles and abstracts of 
the references obtained as a result of our searching activities and exclude obviously 
irrelevant reports. We retrieved the full-text articles for the remaining references and two 
review authors (LCSD and OAE) independently screened the full-text articles and identified 
studies for inclusion, and identified and recorded reasons for excluding ineligible studies. 
We resolved any disagreements through discussion or, if required, we consulted a third 
person (TK). We collated multiple reports of the same study so that each study, not each 
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reference, is the unit of interest in the review. We recorded the selection process and 
complete a PRISMA flow diagram (32). 
2.3.2 Data extraction and management 
Two review authors (LCSD and CFGA) independently extracted data from included studies, 
and recorded data on standard extraction forms created in Microsoft Excel. We extracted 
the following data. 
 
• Methods: study design, randomisation method, allocation concealment method, blinding 
methods. 
• Participants: sample size, age, sex, number of patients originally allocated to each 
treatment group, diagnostic criteria used for aneurysmal SAH and cerebral vasospasm, 
number of patients in each intervention group. 
• Intervention: type of intervention and randomisation, type of anaesthesia, microsurgical 
clipping technique, endovascular coiling technique, endovascular technique used for the 
treatment of cerebral vasospasm (i.e. TBA, IAVI). 
• Outcomes: number of patients in each group with outcomes, including death, neurological 
deficits, and unfavourable outcome; withdrawals and adverse effects; length of follow-up. 
• Other data: publication year, funding sources, intention- to-treat (ITT) analysis; any 
additional important information. 
 
If the two review authors had any disagreements on data extraction, the full review team 
discussed the disagreements and make a final decision. We contacted the original study 
authors for key information when absent in the full text. For dichotomous data, we extracted 
the number of participants experiencing the event and the total number of participants in 
each arm of the trial. For continuous data, we extracted the mean value and standard 
deviation (SD) for the changes in each arm of the trial, along with the total number in each 
group. 
2.3.3 Assessment of risk of bias in included studies 
Two review authors (LCSD y CFGA) independently assessed risk of bias for each study 
using the ROBINS-I tool for non-randomised controlled studies, and for each randomised 
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controlled trials using the criteria outlines in the Cochrane Handbook for Systematic 
Reviews of Interventions (33). We resolved any disagreements by discussion or by 
involving another author (ALC). 
  
Assessment of risk of bias in randomised controlled trials 
Studies that were classified as randomised controlled clinical trials were evaluated using 
the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions 
(33). Two authors (LCSD and CFGA) independently assessed the risk of bias for each 
study, disagreements were resolved by discussion or involving another author (ALC). We 
assessed the risk of bias according to the following domains: 
 
• Random sequence generation; 
• Allocation concealment; 
• Blinding of participants and personnel; 
• Blinding of outcome assessment; 
• Incomplete outcome data; 
• Selective outcome reporting; 
• Other bias. 
 
We judged the risk of bias for each domain to be high, low or unclear. We provided 
information from the study report, together with a justification for our judgement, in the 'Risk 
of bias' tables. 
 
Assessment of risk of bias in non-randomised studies 
Studies that were classified as non-randomised controlled studies were evaluated with the 
ROBINS-I instrument (34). Two authors (LCSD and CFGA) independently assessed the 
risk of bias for each study, disagreements were resolved by discussion or involving another 
author (ALC). The risk of bias was assessed taking into account the following domains: 
 
• Bias due to confounding; 
• Bias in selection of participants into the study; 
• Bias in classification of interventions; 
• Bias due to deviations from intended interventions; 
• Bias due to missing data; 
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• Bias in measurement of outcomes; 
• Bias in selection of the reported result. 
 
The risk of bias was rated for each domain as low, moderate, serious, critical, or no 
information. Information from the report, along with the rationale for the rating, was provided 
in the 'Risk of bias' tables. 
2.3.4 Measures of treatment effect 
For dichotomous data, odds ratios (OR) with 95% confidence intervals (CI) were estimated. 
For continuous data, mean difference (MD) was used if results were measured in the same 
way between studies. Standardized mean difference (SMD) was used to combine studies 
that measured the same outcome but used different methods. The use of a fixed effects 
model was considered in the case of meta-analysis. 
 
When available, non-randomised studies reported adjusted effect estimates (for example, 
adjusted odds ratios from logistic regression analysis), these were preferable to analyzes 
based on summary statistics, as they generally reduce the impact of confounders. 
Therefore, the adjusted effect estimates that were reported by the authors of each study 
and the variables used for their adjustment were recorded. 
2.3.5 Unit of analysis issues 
We consider each participant as the unit of analysis. If any non-typical design was found 
(i.e. cluster or crossover randomised trials), we considered applying the Cochrane 
Handbook recommendations for systematic reviews of interventions (35). 
 
In those studies, reporting multiple measurements of outcomes within a single time period 
(i.e. long-term unfavourable outcome, short-term unfavourable outcome, and quality of life), 
we included the longest follow-up inside each period. To assess the effect of this procedure 
on the estimation of the effect, we considered doing a sensitivity analysis dividing the long-
term follow-up in the following intervals: three to six, six to 12 months, 12 to 24 months, and 
over 24 months (35). 
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2.3.6 Dealing with missing data 
Attempts were made to contact study authors to obtain incomplete or missing information 
that was not mentioned in the abstract or full text article. We performed an intention-to-treat 
analysis for each outcome included in the protocol. In the event of incomplete or missing 
information, we perform a best and worst-case scenario analysis, such as a sensitivity 
analysis, in accordance with the recommendations of the Cochrane Handbook for 
Systematic Reviews of Interventions (36). 
2.3.7 Assessment of heterogeneity 
We assessed heterogeneity in study design and population. We considered to use the I2 
statistic to measure heterogeneity among the trials in each analysis. An I2 value 60% or 
greater would be considered to indicate moderate to substantial heterogeneity, and we 
would try to explain possible sources of heterogeneity by subgroup analysis or meta-
regression (36). 
2.3.8 Assessment of reporting bias 
We considered to use funnel plots to assess the risk of reporting bias only if we find more 
than 10 studies. We would interpret these graphs according to the guidance in the 
Cochrane Handbook for Systematic Review of Interventions (36). 
2.3.9 Data synthesis 
Where we considered studies to be sufficiently similar, we would conduct a meta-analysis 
by pooling the appropriate data using Review Manager 5 (37). We would use a random-
effects model if we identified significant heterogeneity. 
2.3.10 Subgroup analysis and investigation of heterogeneity  
In the case of data synthesis, we would perform these analyses for all outcomes according 
to the following subgroups: 
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§ Risk groups for cerebral vasospasm, assessed using the Fisher's scale (38),  see 
Appendix 1. 
§ Patients with poor-grade aneurysmal SAH (Hunt & Hess grade 4 and 5, World 
Federation of Neurosurgical Societies (WFNS) grade 4 and 5) compared to non-poor-
grade aneurysmal SAH patients (39), see Appendix 1. 
2.3.11 Sensitivity analysis  
In the case of data synthesis when we find six or more studies included in a single analysis, 
we would conduct a sensitivity analysis to assess the effect of the risk of bias on the results 
of the meta-analysis. We would re-analyse data after excluding: 
 
§ trials within adequate or unclear allocation concealment; 
§ trials with unclear or no blinding of outcome assessment; 
§ trials in which the description of the intervention is uncertain; 
§ trials with other biases or where the presence of bias is uncertain; 






3.1 Description of studies 
3.1.1 Results of the search 
In total, 2098 references were retrieved and 1680 were assessed after eliminating 
duplicates. Of these, 77 full text articles were initially analyzed and considered probable 
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Figure 3-1: Flow diagram (PRISMA). 
 
Source: Own elaboration. 
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3.1.2 Included studies 
The 26 included studies involved a total of 1854 participants. Sample size ranged between 
12 and 231 participants. These studies were conducted in Germany (45,46,58), Australia 
(49), Austria (43), Canada (53,54,59,62), South Korea (48),   the United States 
(21,41,47,52–54,56,59,61,63,64), France (60), India (42), Japan (44,50,55,57), Mexico (40) 
and Switzerland (51). Three studies were multicenter trials (53,54,59), one study used a 
randomised method to assign the intervention and was conducted prospectively (55), and 
the remaining studies were retrospective. All included studies were written in English.  
 
Population 
The included studies recruited men and women over the age of 18. The most common 
diagnostic method used to confirm the presence of aneurysmal subarachnoid haemorrhage 
(SAH) was computed tomography in six studies (40,41,49,56,61,63), followed by lumbar 
puncture in three (41,56,63), and magnetic resonance imaging in two (56,61),  20 studies 
did not report the SAH diagnostic strategy utilized (21,42–48,50–55,57–60,62,64)1.  
 
Clinical severity was established using the Hunt-Hess scale (65) and the World Federation 
of Neurosurgical Societies grading system (66). Thus, poor clinical condition was 
considered when scores defined grade III to V on the Hunt-Hess scale, or 4 and 5 on the 
World Federation of Societies of Neurosurgery scale (67,68) (Appendix 1). The frequency 
of poor clinical condition was between 17% and 87%. 
 
The Fisher scale was used to evaluate the risk of vasospasm, with a classification 









1 Some studies used multiple diagnostic tests for SAH (41,56,61,63). 





The vasodilators evaluated were colforsin (57), fasudil (50), milrinone (60,62), nicardipine 
(47,48,61), nimodipine (40,42,45,46,51,58), papaverine (41,43–45,49,52–55,57,59,63,64), 
magnesium sulphate (47), and verapamil (41,47,49,56).   
 
The dose of colforsin used was 3mg diluted in 100 mL of saline solution (57). Intra-arterial 
fasudil at an infusion rate of 3 mg/min was utilized selectively and non-selectively (50). 
When milrinone was used, the intra-arterial dose was between 8 and 24mg (60). 
Nicardipine was used at a dose between 1 and 15mg as monotherapy (61) and between 2 
and 3mg in combination with angioplasty and stent placement (48) .  
 
Similarly, the doses of nimodipine used were between 0.2mg and 6mg (40,42,45,46,51,58). 
Finally, the concentration of papaverine was between 0.1 and 2% (55); the most frequent 




The most frequently used type of balloon was compliant (21,40,47,49,52). Only one study 
compared the use of compliant balloon with non-compliant balloon (21), while the remaining 
studies did not report the type of balloon used (41,43,44,46,51,53,56,59,62,63).  
 
Stent:  
Additionally, one study reported the use of retrievable stents in combination with intra-
arterial vasodilator infusion (48). 
 
Comparisons 
Endovascular versus medical treatment: 
Eleven studies used medical treatment as a control group and eight of them compared it 
with intra-arterial vasodilator infusion (42,44,50,54,58,60–62), one with balloon angioplasty 
(44)2, and three with intra-arterial vasodilator infusion plus balloon angioplasty (47,49,53). 
 
 
2 The study by Katoh et al. (44) included two comparisons. 
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  Intra-arterial vasodilator infusion versus balloon angioplasty: 
Seven studies compared intra-arterial vasodilator infusion with balloon angioplasty 
(40,44,52,56,59,63,64). 
 
Intra-arterial vasodilator infusion versus another intra-arterial vasodilator: 
Two studies compared vasodilators. One of them compared papaverine vs. nimodipine (45) 
and the other compared papaverine vs. colforsin (57).  
 
Intra-arterial vasodilator infusion versus combination therapy (IAVI + TBA): 
Three studies compared intra-arterial vasodilator infusion with intra-arterial vasodilator 
infusion plus percutaneous transluminal balloon angioplasty (41,43,46). 
 
Balloon angioplasty versus combination therapy (IAVI + TBA):  
One study compared balloon angioplasty with combined endovascular therapy (IAVI + 
TBA) (56). 
 
Compliant balloon angioplasty versus non-compliant balloon angioplasty: 
One study compared the use compliant balloon angioplasty with non-compliant (21). 
 
Comparison between sequences of vasodilator infusion while stent retriever 
therapy: 
One study evaluated nicardipine infusion associated with the use of a recoverable stent, 
comparing the sequence of application of the vasodilator (before using the stent vs. after 
using the stent) (48).  
 
Comparison between different doses of the same intra-arterial vasodilator:   
One study (55) randomly compared three different intra-arterial papaverine concentrations, 
one group received 0.2% papaverine, the second group 0.4% papaverine, and the third 
group received 0.8-2%. 
 
Comparison between different number of endovascular therapy sessions: 
Finally, one study compared the number of sessions carried out using intra-arterial 
vasodilator infusion plus balloon angioplasty (51). One group received 1 to 2 sessions vs. 
the other group that received 3 to 6 sessions of combination therapy, as described above. 




The included studies reported at least one primary outcome pre-specified in this review. 
However, there were some differences in the reporting and definition of results between 
studies.  
 
Unfavourable outcome was assessed using the modified Rankin Scale (mRS) and the 
Glasgow Outcome Score (GOS). Thirteen studies reported unfavourable outcomes at 
hospital discharge (21,41,42,44,45,50,52,56–58,61), and nine studies reported the 
outcome after three months or more of follow-up (40,42,49,51,53,54,58,60,63).  
 
Mortality during follow-up was reported in 14 studies (40,44,45,47–51,53,54,58,60,61,63). 
The appearance of ischaemic lesions during follow-up tomography or magnetic resonance 
was described in 11 studies (21,40,43,45,50,51,53,54,57,58,61). 
 
The included studies also reported improvement of neurological symptoms after treatment, 
improvement after treatment with angiography, hospital stay, and adverse events. No data 
on costs associated with the treatments, nor on quality of life during follow-up, were 
obtained. 
 
Length of follow-up 
Participants were monitored for 3 months (42,43,53,54) or 12 months (47,51,60). 
3.1.1 Risk of bias in the included randomised trials   
The assessment of risk of bias in the randomised trials analyzed is summarized in Table 3-
1, including the only article that used a randomised method for intervention allocation (55). 
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Table 3-1: Assessment of the risk of bias in the study by Sawada et al. (55) 
Item Assessment Support for assessment 
Random sequence 
generation (selection 
bias)   
 
Unclear risk 
The researchers did not describe the 
strategy used for generating the 
sequence: “The assignment of patients 
into these three groups was performed 
at random.” 
Allocation concealment 
(selection bias) Unclear risk 
There was not enough information to 
judge this item. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk of bias 
The impact of participant and staff 
blinding was considered to be of little 
relevance to the outcomes assessed in 
the study. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk It did not specify whether evaluators were blinded. 
Incomplete outcome 
data (attrition bias) Unclear risk 
No losses were reported during follow-
up. 
Selective reporting 
(reporting bias) Unclear risk 
There was no access to the protocol 
for assessment. 
Other sources of bias Low risk No additional issues 
 
3.1.2 Risk of bias in the included non-randomised trials 
The assessment of the risk of bias of non-randomised trials is summarized in Figures 3-2 
and 3-3. Furthermore, additional details of the studies included are provided in the 
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Figure 3-2: Risk of bias assessment in non-randomised studies using the ROBINS-I tool. 
 
Source: Own elaboration. 
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Figure 3-3: Summary of risk of bias assessments in non-randomised trials using the 
ROBINS-I tool. 
 
Source: Own elaboration. 
 
Bias due to confounding 
All included studies had some degree of risk of confounding; therefore, no study was rated 
as low risk of bias. Nine studies (44,46,47,53,54,56–59) were rated as moderate risk of 
bias, three studies used historical cohorts as control group (47,57,58), five studies used 
multivariate analysis to assess the effect of covariates on outcomes (47,54,56,57,59), and 
three studies nested the population recruited in a controlled clinical experiment and 
performed a paired-control analysis (53,54,59). Finally, two studies clearly defined the 
selection criteria for the comparison groups with an adequate balance of covariates at 
baseline (44,46). 
 
Twelve studies were rated as having serious risk of bias, of which seven did not clearly 
present the criteria to allocate participants to the intervention groups 
(21,40,43,48,50,61,62). On the other hand, five studies used different criteria between the 
two comparison groups (42,45,52,60,61), and eight did not use multivariate analysis 
methods to control for confounding factors (40,45,48,52,60–63). 
 
The remaining three studies were at critical risk of bias (41,49,51), and used inclusion 
criteria related to the outcome; patients were allocated to the intervention groups according 
to the severity of the disease. Furthermore, the statistical methods used were insufficient 
to control the risk of bias. 
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Bias due to selection of participants into the study 
One study (41) changed the intervention to which the patients were allocated based on the 
angiographic response after its performance, which generated a critical risk of bias. In 
addition, three studies (51,58,61) modified the intervention groups according to the 
response obtained during treatment, which led to a moderate risk of bias. One study (62) 
no proporcionó suficiente información para establecer el riesgo de sesgo. did not provide 
sufficient information to establish risk of bias. The remaining 19 studies had no problems in 
the selection criteria of subjects; therefore, the risk of selection bias was low for this domain 
(21,40,42–50,52–54,56,57,59,60,63).  
 
Bias in classification of interventions 
Two studies (41,42) were rated at risk of serious bias. Frontera et al. allocated the 
participants to the intervention groups during the process, making unclear how the control 
groups were defined. Goel et al. did not provide a clear definition of the control group.  
 
Three studies (40,50,61) included findings in angiography as an intervention allocation 
criterion and were, therefore, considered at risk of moderate bias. One study (62) did not 
provide sufficient information to assess risk of bias. The remaining studies, on the other 
hand, provided an adequate definition of the interventions and were considered at low risk 
of bias for this domain (21,43–49,51–54,56–60,63,64). 
 
Bias due to deviations from intended interventions  
Two studies (41,43) made changes in intervention allocation during follow-up according to 
responses or development of new symptoms. This circumstance was classified as a risk of 
serious bias. 
 
Elliot et al. changed the intervention groups systematically and asymmetrically. The criteria 
for receiving a second therapy were different between the groups; this was assessed as a 
risk of critical bias (63). One study did not provide sufficient information to establish risk of 
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Bias due to missing data 
Three studies were rated as no low risk of bias. In one of them was rated at moderate risk 
of bias (43), the authors reported a significant number of losses; however, it did not have a 
significant effect on the balance of the groups. The second study was rated at serious risk 
of bias (60),  excluded all cases with missing data and did not analyze the excluded 
population. The third study (62) did not provide sufficient information to establish risk of 
bias. The remaining studies showed a low risk of bias for this domain (21,40–42,44–54,56–
59,61,63,64). 
 
Bias in measurement of outcomes 
In Kerz et al., outcomes were assessed by the same person who administered the 
intervention; therefore, it was rated as a risk of serious bias (45). In eight studies (42,46–
48,50,56,57,63), although the evaluator was a third party, it probably knew the type of 
intervention administered to the patient, so risk of bias was considered moderate. The 
remaining studies showed a low risk of bias for this domain (21,40,41,43,44,49,51–54,58–
62,64). 
 
Bias in selection of the reported result 
19 studies had a potential source of bias related to the selective reporting of outcomes, as 
the protocol of the studies could not be verified (21,41–52,56–58,60,62,63). The remaining 
studies showed a low risk of bias for this domain (40,53,54,59,61,64). 
 
Overall Risk of Bias judgement  
A total of 24 studies were assessed using the ROBINS-I instrument. We did not evaluate 
one study (64)  because it did not report any one of the outcomes of interest in this review. 
Ten studies (42%) showed a moderate risk of bias (44,46–48,53,54,56–59), ten studies 
(42%) were rated as a risk of serious bias (21,40,42,43,45,50,52,60–62), and four studies 
(16%) were rated as a risk of critical bias (41,49,51,63).  
 
The confounding bias domain had the largest number of qualified studies at risk of  
serious-critical bias. The selective outcome reporting domain showed a high frequency of 
studies rated as moderate risk of bias. The domains with the most studies at low risk of bias 
were bias due to selection of participants, bias in classification of interventions, bias due to 
deviations from intended interventions, and bias due to missing data. 
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3.2 Effect of Interventions 
3.2.1 Intra-arterial vasodilators versus medical therapy 
Eight studies involving 479 patients compared intra-arterial vasodilator infusions with 
standard medical therapy (42,44,50,54,58,60–62). Those studies contributed data for some 
outcomes. 
 
Long-term unfavourable outcome 
The information obtained corresponded to the results of four studies (42,54,58,60). Intra-
arterial vasodilator infusion was associated with an unfavourable outcome at three to twelve 
months in between 24% and 55% of the cases, compared with medical therapy, which is 
estimated at between 23% and 90%. Only the Bele et al. study showed statistically 
significant differences in this outcome (OR 0.1, CI 95% 0.02-0.52), the results of the 
multivariate logistic regression did not show any statistically significant association. The 
other three studies showed no significant differences, neither they reported any significant 
association on multivariate analysis for this outcome. 
 
Short-term unfavourable outcome 
The information obtained corresponded to the results of four studies (42,44,50,58). Intra-
arterial vasodilator infusion showed unfavourable outcomes between 50% to 100% of the 
cases during patient discharge, compared with figures between 48% and 90% in medical 
therapy. No study showed a statistically significant difference in this outcome. No study 
reported multivariate analysis for this outcome. 
 
Mortality 
The information obtained corresponded to the results of five studies (44,50,58,60,61). Intra-
arterial vasodilator infusion had 0% to 44% mortality rates during follow-up, compared with 
medical therapy, which showed mortality between 3% and 35%. No study showed a 
statistically significant difference in this outcome. No study reported multivariate analysis 
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Cerebral infarction 
The information obtained corresponded to the results of four (50,54,58,61). Intra-arterial 
vasodilator infusion was involved in between 9% to 85% of delayed cerebral infarctions as 
per computerized tomography during follow-up, compared with medical therapy, which was 
between 0% and 80%. Two studies showed statistically significant differences, Bele et al. 
showed an OR 0.25 (95% CI 0.07-0.95) and Besheli et al. showed an OR 22.8 (95% CI 
1.05-4.93); the remaining studies did not show statistically significant differences. No study 
reported multivariate analysis for this outcome. 
 
Neurological deficit improvement 
La información obtenida correspondió a los resultados de un estudio (42). Intra-arterial 
vasodilator infusion was associated with improvement after the treatment of neurological 
deficit in 72%, as compared with medical therapy that showed 43% (a difference without 
statistical significance). This study did not report any multivariate analysis for this outcome. 
 
Angiographic improvement of cerebral vasospasm 
The information obtained corresponded to the results of one study (62). Intra-arterial 
vasodilator infusion showed angiographic improvement in 90% of cases compared with 
11% (p<0.0001) of angiographic improvement in the medical treatment group, with an 
estimated OR 75 (CI 95% 25-216). This study did not report any multivariate analysis for 
this outcome. 
 
Length of hospital stay 
The information obtained corresponded to the results of one study (61). Intra-arterial 
vasodilator infusion showed an 18-day stay in ICU compared with the medical treatment 
group with a 12.2-day stay period (p<0.001). This study did not report any multivariate 
analysis for this outcome. 
 
Adverse events 
La información obtenida correspondió a los resultados de tres estudios (50,58,60). Intra-
arterial vasodilator infusion showed 10% to 50% adverse events compared with medical 
treatment, which showed between 0% and 46% adverse events. No study showed a 
statistically significant difference for this outcome. No study reported multivariate analysis 
for this outcome. 
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3.2.2 Balloon angioplasty versus medical therapy 
One study with 52 patients compared balloon angioplasty versus standard medical therapy 
(44). Data were not obtained for any of the outcomes. 
 
Short-term unfavourable outcome 
Balloon angioplasty showed unfavourable outcome at hospital discharge in 50% of the 
cases compared with 48% of medical therapy. The difference was not statistically significant 
(44). This study did not report any multivariate analysis for this outcome. 
 
Mortality 
Balloon angioplasty showed 0% mortality compared with 12% mortality of medical therapy. 
The difference was not statistically significant (44). This study did not report any multivariate 
analysis for this outcome. 
3.2.3 Intra-arterial vasodilator plus balloon angioplasty versus 
medical therapy 
Three studies involving 347 patients compared intra-arterial vasodilator infusion plus 
balloon angioplasty with standard medical therapy (47,49,53). Those studies contributed 
data for some outcomes. 
 
Long-term unfavourable outcome 
The information obtained corresponded to the results of two studies (49,53).  Intra-arterial 
vasodilator infusion plus balloon angioplasty showed unfavourable outcomes at three 
months in between 6% and 47% of the cases, compared with 17% and 40% in medical 
therapy. No study showed a statistically significant difference in this outcome. These 
studies did not report any multivariate analysis for this outcome. 
 
Short-term unfavourable outcome 
The information obtained corresponded to the results of two studies (47,49). Intra-arterial 
vasodilator infusion plus balloon angioplasty showed between 33% and 53% unfavourable 
outcomes during patient discharge compared with 45% of medical therapy. No study 
showed a statistically significant difference in this outcome. Khatri et al. reported the result 
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of the multivariate analysis adjusted for age, severity and type of aneurysm treatment, 
without statistically significant association.  
 
Mortality 
The information obtained corresponded to the results of two studies (47,49). Intra-arterial 
vasodilator infusion plus balloon angioplasty showed mortality rates between 0% to 23% 
during follow-up, compared with medical therapy, which showed between 3% and 32%. No 
study showed a statistically significant difference in this outcome. Khatri et al. reported the 
result of the multivariate analysis adjusted for age, severity and type of aneurysm treatment, 
without statistically significant association.  
 
Length of hospital stay 
The information obtained corresponded to the results of two studies (47,49). The length of 
hospital stay in cases treated with intra-arterial vasodilator infusion plus balloon angioplasty 
was between 15 and 27 days, compared with a length of hospital stay between 17 and 22 
days in the control group. Differences were not statistically significant. These studies did 
not report any multivariate analysis for this outcome. 
 
Mortimer et al. (49) reported a stay in the intensive care unit in the vasodilator infusion 
group of 20 days and 12 days in the control group, a MD of 7.9 days was estimated (95% 
CI 6.49-9.31, p<0.0001). These studies did not report multivariate analysis for this outcome. 
 
Adverse events 
The frequency of adverse events was reported in one study (49). Intra-arterial vasodilator 
infusion plus balloon angioplasty showed a 6% frequency of adverse events, compared 
with no adverse events of medical treatment (p=0.21). No statistical significance was 
shown. This study did not report any multivariate analysis for this outcome.  
3.2.4 Intra-arterial vasodilator versus balloon angioplasty 
Seven studies involving 280 patients compared intra-arterial vasodilator infusion with 
balloon angioplasty (40,44,52,56,59,63,64). Those studies contributed data for some 
outcomes. 
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Long-term unfavourable outcome 
One study reported long-term unfavourable outcomes (40). Intra-arterial vasodilator 
infusion was associated with 23% of unfavourable outcomes at 12 months, compared with 
38% of balloon angioplasty. Intra-arterial vasodilator infusion was associated with 45% of 
unfavourable outcomes at 3 months, compared with 50% of balloon angioplasty. The 
difference was not statistically significant. This study did not report any multivariate analysis 
for this outcome. 
 
Short-term unfavourable outcome 
The information obtained corresponded to the results of four studies (44,52,56,63). Intra-
arterial vasodilator infusion showed between 38% and 85% unfavourable outcomes during 
patient discharge compared with 33% to 73% of balloon angioplasty. No study showed a 
statistically significant difference in this outcome. 
Sokolowski et al. (56) reported the result of the multivariate analysis for an unfavourable 
outcome at discharge, the regression model included age, history of cigarette smoking, 
arterial hypertension, severity on admission and presence of symptoms, they reported a 
non-significant difference between the two groups; the remaining studies did not show 




The information obtained corresponded to the results of three studies (40,44,63). Intra-
arterial vasodilator infusion showed 0% to 25% mortality, compared with balloon 
angioplasty, which showed between 0% and 38% mortality. No study showed statistically 




One study reported delayed infarction on control tomography (40). Intra-arterial vasodilator 
infusion was observed in 95% of cerebral infarction cases during CT, compared with 100% 
of balloon angioplasty. The difference was not statistically significant. This study did not 
report any multivariate analysis for this outcome. 
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Neurological deficit improvement 
These data comes from the results of three studies (44,52,59). Intra-arterial vasodilator 
infusion showed 25% to 50% neurological deficit improvement, compared with balloon 
angioplasty, which showed improvements between 29% and 58%. No study showed a 
statistically significant difference for this outcome.  These studies did not report any 
multivariate analysis for this outcome. Coenen et al. reported the result of the multivariate 
analysis that did not show significant differences between the two groups, the rest of the 
studies did not report multivariate analysis for this outcome.  
 
Improvement of angiographic vasospasm 
Two studies reported improvement of angiographic vasospasm between 93% and 100% of 
patients receiving intra-arterial vasodilator infusion and 100% of patients receiving balloon 
angioplasty (56,63). There was no statistical significance. These studies did not report any 
multivariate analysis for this outcome.  
 
Adverse events 
Two studies reported the frequency of serious adverse events (44,63). Intra-arterial 
vasodilator infusion had no serious complications compared with balloon angioplasty with 
one adverse event (2.5%). There was no statistical significance. This study did not report 
any multivariate analysis for this outcome. 
3.2.5 Intra-arterial vasodilator versus intra-arterial vasodilator 
plus balloon angioplasty 
Five studies involving 388 patients compared intra-arterial vasodilator infusion (IAVI) versus 
combined endovascular therapy with IAVI plus balloon angioplasty (TBA) (41,43,46,52,56). 
Those studies contributed data for some outcomes. 
 
Short-term unfavourable outcome 
Three studies assessed unfavourable outcomes at the time of patient discharge (41,52,56). 
The proportion of 38% to 80% adverse outcomes was found in the group  that received 
combined endovascular therapy (IAIV + TBA) versus the group that received intra-arterial 
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vasodilator infusion that was 40% to 85% (52,56). Frontera y col. (41) reported a binary 
logistic regression model with an OR 0.6 (95%CI 0.2–1.7, p=0.351). 
 
Cerebral infarction 
One study reported the frequency of delayed cerebral infarction during control tomography 
(43). Intra-arterial vasodilator infusion had a frequency of 25.5% in delayed cerebral 
infarctions observed through computerized tomography during follow-up, compared with 
36% in patients that received combined endovascular therapy (IAVI + TBA); this is not a 
statistically significant difference. This study reported multivariate analysis for this outcome, 
without evidence of a statistically significant association (the variables included were the 
clinical severity of SAH, days of treatment, severity of vasospasm, and number of 
interventions). 
 
Neurological deficit improvement 
One study reported the frequency of neurological recovery after treatment (52). Intra-arterial 
vasodilator infusion showed a neurological recovery frequency of 45%, compared with 
combined endovascular therapy (IAVI + TBA), which was 62% (difference without statistical 
significance). This study did not report multivariate analysis for this outcome. 
 
Improvement of angiographic vasospasm 
The information obtained corresponded to the results of three studies (41,43,56). Intra-
arterial vasodilator infusion showed angiographic improvements in 30% to 93% of patients, 
compared with 50% to 100% of angiographic improvements in the combined endovascular 
therapy group (IAVI + TBA). Differences were not statistically significant. These studies did 
not report any multivariate analysis for this outcome.  
 
Adverse events 
The information obtained corresponded to the results of one study (46). Intra-arterial 
vasodilator infusion showed a frequency of 0% of adverse events compared with adverse 
events of 19% in patients that received combined endovascular therapy (IAVI + TBA). No 
study showed a statistically significant difference for this outcome. These studies did not 
report any multivariate analysis for this outcome. 
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3.2.6 Balloon angioplasty versus intra-arterial vasodilator plus 
balloon angioplasty 
Dos estudios que incluyeron 75 pacientes comparó la angioplastia con balón versus la 
terapia endovascular combinada (IAVI + TBA) (52,56). Data were not obtained for any of 
the outcomes. 
 
Short-term unfavourable outcome 
Balloon angioplasty was associated with unfavourable outcomes at discharge between 
42% to 73% of patients, compared with 39% to 80% of combined endovascular therapy 
(IAVI + TBA). The difference was not statistically significant (52,56). Only Sokolowski et al. 
reported a multivariate analysis, it did not show any significant association (56). 
 
Neurological deficit improvement 
Balloon angioplasty showed neurological recovery in 50% of the patients, compared with 
combined endovascular therapy (IAVI + TBA), which was 62%. There was no statistical 
significance (52). This study did not report multivariate analysis for this outcome. 
 
Improvement of angiographic vasospasm 
Balloon angioplasty showed improvement of angiographic vasospasm in 100% of patients, 
compared with 100% of combined endovascular therapy (IAVI + TBA). There was no 
statistically significant differences (56). This study did not report any multivariate analysis 
for this outcome. 
 
Adverse events 
Neither balloon angioplasty nor combined endovascular therapy (IAVI + TBA) showed 
serious adverse events (56). No adverse events were identified. 
3.2.7 Intra-arterial vasodilator versus intra-arterial vasodilator 
Three studies involving 117 patients compared two or more regimes of intra-arterial 
vasodilator infusion (45,55,57). One study compared three different concentrations of 
papaverine (55), one study compared nimodipine versus papaverine (45) ), and one study 
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compared papaverine versus colforsin (57). Those studies contributed data for some 
outcomes. 
 
Short-term unfavourable outcome 
The information obtained corresponded to the results of two studies (45,57). In Kerz et al., 
intra-arterial infusion of papaverine showed an unfavourable outcome at discharge in 47% 
of patients, compared with 33% (p>0.05) of intra-arterial infusion of nimodipine, without any 
statistical significance (45). However, Suzuki et al. reported unfavourable outcomes at the 
discharge in 34% of patients receiving intra-arterial infusion of colforsin, compared with 
66% of papaverine infusion (p=0.032). The difference was not statistically significant (57). 
Also, Suzuki et al. reported the results of the multivariate analysis (included age, sex, 
clinical severity, surgery) that reported OR 5.61 (95% CI 1.54-20.43). 
 
Mortality 
The information obtained corresponded to the results of two studies (45,57). In Kerz et al., 
the intra-arterial infusion of papaverine showed 0% mortality, compared with 33% (p< 0.05) 
of intra-arterial infusion of nimodipine, showing significant statistical differences (45). In 
Suzuki et al., the intra-arterial infusion of colforsin showed an unfavourable outcome at 
discharge in 0% of patients, compared with 15% (p>0.05) of intra-arterial infusion of 
papaverine, without any statistical significance (57). These studies did not report any 
multivariate analysis for this outcome. 
 
Cerebral infarction 
Two studies assessed the presence of delayed cerebral infarction during control brain 
imaging (45,57). The intra-arterial colforsin infusion group showed a cerebral infarction rate 
of 62%, compared with 85% of the papaverine infusion group (p=0.039) (57). The difference 
was not statistically significant. This study did not report any multivariate analysis for this 
outcome. 
 
The group of intra-arterial infusion of nimodipine showed a frequency of cerebral infarction 
of 67%, compared to the infusion of papaverine that was 53% (p = 0.71), the difference was 
not statistically significant (45); this study did not report multivariate analysis for this 
outcome. 
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Neurological deficit improvement 
The information obtained corresponded to the results of one study (55). Intra-arterial 
infusion of papaverine was administered continuously at 3 different concentrations: 0.1-
0.2%, 0.4% and 0.8-2%. The first group showed an improvement of 21% in neurological 
symptoms; the second, 44%, and the third, 6%. A statistically significant difference was 
found with the second group, which had greater improvement in neurological symptoms, 
compared with the third group. This study did not report any multivariate analysis for this 
outcome. 
 
Angiographic improvement of cerebral vasospasm 
The information obtained corresponded to the results of two studies (45,55). In Kerz et al., 
intra-arterial infusion of papaverine showed 60% of angiographic improvement compared 
with 33% of intra-arterial infusion of nimodipine (p< 0.01). Outcomes showed statistically 
significant differences (45).  
 
In Sawada et al., intra-arterial papaverine infusion was administered continuously at 3 
different concentrations: 0.1-0.2%, 0.4% and 0.8-2%. The first group showed 47% of 
angiographic improvement; the second, 80%, and the third, 20%. Infusion at 0.4% 
concentration showed to be statistically higher than the other two groups. These studies 
did not report any multivariate analysis for this outcome (55). 
 
Length of hospital stay 
The information obtained corresponded to the results of one study (45). Intra-arterial 
infusion of papaverine showed an average length of hospital stay of 28.3 ± to 13.2 days 
compared with 26.2±11 days in the nimodipine infusion group. There were no statistically 
significant differences. This study did not report any multivariate analysis for this outcome. 
 
Adverse events 
The information obtained corresponded to the results of two studies (55,57). Intra-arterial 
infusions of papaverine and colforsin did not show any serious adverse event (57).  
 
In Sawada et al., intra-arterial papaverine was administered continuously at 3 different 
concentrations: 0.1-0.2%, 0.4% and 0.8-2%. 7% of the patients in the first group, 6% in the 
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second, and 44% in the third group developed adverse events. The 0.82% concentration 
infusion group showed that the number of adverse events with statistical significance was 
higher than in the other two groups. These studies did not report any multivariate analysis 
for this outcome (55). 
3.2.8 Compliant balloon angioplasty versus non-compliant 
balloon angioplasty versus non-compliant balloon 
angioplasty 
One study involving 30 patients compared compliant balloon angioplasty versus non- 
compliant balloon angioplasty (21). No data was obtained for all outcomes. 
 
Short-term unfavourable outcome 
Compliant balloon angioplasty showed a short-term unfavourable outcome rate of 60%, 
compared with non-compliant balloon angioplasty, which was 25% (p = 0.1); without 
statistical significance. This study did not report multivariate analysis for this outcome. 
 
Mortality 
Compliant balloon angioplasty showed a mortality of 20%, compared with non-compliant 
balloon angioplasty, which was 20% (p = 1); without statistical significance. This study did 
not report multivariate analysis for this outcome. 
 
Cerebral infarction 
Compliant balloon angioplasty was associated with 21% of delayed cerebral infarctions 
during follow-up compared with 10% of non-compliant balloon angioplasty (p=0.21). There 
were no statistically significant differences. This study reported the result of the multivariate 
analysis for this outcome: OR 1.7 95% CI (0.51-5.8, p = 0.39). 
 
Adverse events 
There were no serious adverse events from compliant balloon angioplasty or non-compliant 
balloon angioplasty in the study. 
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3.2.9 Number of intra-arterial vasodilators plus balloon 
angioplasty sessions 
One study involving 83 patients compared 1-2 sessions versus 3-6 sessions of intra-arterial 
vasodilator treatment for vasospasm (51). No data was obtained for all outcomes. 
 
Long-term unfavourable outcome 
Treatments administered in 1-2 sessions showed unfavourable outcomes at last follow-up 
(mean 11 ± 6.3 months) in 40% of cases, compared with 42% of 3-6 sessions (p>0.05) 
(51). There were not statistically significant differences. This study did not report any 
multivariate analysis for this outcome.  
 
Short-term unfavourable outcome 
Treatments administered in 1-2 sessions showed unfavourable outcomes in 69% of 
patients when discharged, compared with 84% of 3-6 sessions (p>0.05) (51). There were 




The rate of cerebral infarction in treatments administered in 1-2 sessions 1 was 35% 
infarction during control tomography, compared with 55% of 3-6 sessions (p>0.05) (51). 
There were not statistically significant differences. This study did not report any multivariate 
analysis for this outcome. 
 
Cerebral infarction 
The rate of cerebral infarction in treatments administered in 1-2 sessions 1 was 35% 
infarction during control tomography, compared with 55% of 3-6 sessions (p>0.05) (51). 
There were not statistically significant differences. This study did not report any multivariate 
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Adverse events 
The frequency of adverse events was 2% in the 1-2-session treatment group, compared 
with the 16% (p>0.05) of 3-6-session group (51). There were not statistically significant 
differences. This study did not report any multivariate analysis for this outcome. 
 
3.2.10 Stent retriever plus intra-arterial vasodilator 
One study in 12 patients compared treatment using a stent retriever. One of the groups 
received 3-5 mg of nicardipine intra-arterially followed by angioplasty with retrievable stent, 
while the other group received angioplasty with retrievable stent prior to the administration 
of nicardipine (48). Information on all the outcomes was not available. 
 
Short-term unfavourable outcome 
Administration of nicardipine before stent placement showed an unfavourable outcome of 
40% compared to stent placement before administering nicardipine, which was 29%. The 
difference was not statistically significant (48). This study did not report multivariate analysis 
for this outcome. 
 
Mortality 
No mortality events occurred or were reported in the study (48). 
 
Neurologic deficit improvement  
Nicardipine before placing a retrievable stent showed neurological improvement in 60% of 
the cases, compared to the use of the retrievable stent prior to the administration of 
nicardipine which was 85.7%. The difference was not statistically significant (48). This study 
did not report any multivariate analysis for this outcome. 
 
Improvement of angiographic vasospasm 
Nicardipine before placing the retrievable stent showed angiographic improvement in 71% 
of the sample, compared to the use of the retrievable stent prior to nicardipine 
administration which was 82%. The difference was not statistically significant (48). This 
study did not report any multivariate analysis for this outcome. 
 
Chapter 3 43 
 
Adverse events 
Nicardipine before placing the retrievable stent was associated with adverse events in 20% 
of patients (events), compared to the use of the retrievable stent prior to nicardipine 
administration in 29% of them. The difference was not statistically significant (48). This 







4.1 Summary of main results 
Twenty-six studies (1783 participants) met the inclusion criteria. Of these, 25 were non-
randomised controlled studies and one was a randomised controlled clinical trial. 
Furthermore, 11 studies compared some type of endovascular treatment with conventional 
medical therapy and the other 15 compared different endovascular treatments with each 
other. 
 
Eleven studies (871 participants) addressed the use of endovascular treatment and medical 
therapy. Seven of these studies compared endovascular treatment to intra-arterial 
vasodilator infusion (IAVI), three compared it to combination therapy (IAVI + TBA), and one 
study compared three groups (medical therapy vs. IAVI vs. TBA).  
 
When comparing the use of intra-arterial vasodilator infusion (IAVI) to medical therapy, 
statistically significant evidence was found in favor of IAVI over medical therapy. The 
frequency of unfavourable outcomes at 3 months was lower in patients who received IAVI 
(52% vs. 90%, p=0.01), and angiographic improvement was higher in patients who received 
IAVI (90% vs. 10%, p<0.001). However, intensive care unit stay was longer in the IAVI 
group (18 days vs. 12.2 days, p<0.001). No statistically significant differences were found 
regarding the other outcomes reported in the studies that compared endovascular therapy 
(IAVI, TBA, or IAVI + TBA) to medical therapy. The risk of bias in these studies was 
moderate-serious.   
 
Seven studies (280 patients) compared intra-arterial infusion of vasodilators (IAVI) to 
balloon angioplasty (TBA). Outcomes included mortality, delayed cerebral infarction on 
brain imaging, neurologic/angiographic improvement, unfavourable outcome at discharge, 
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unfavourable outcome in the long-term, and adverse events. None of the studies 
demonstrated statistically significant differences for or against the interventions evaluated. 
The risk of bias was moderate-critical. 
 
On the other hand, five studies (388 patients) compared combined therapy (IVIA + TBA) to 
the administration of these interventions separately, no statistically significant differences. 
The risk of bias was moderate-serious-critical.  
 
Three studies (117 patients) compared different intra-arterial vasodilators with each other; 
one of them was randomised. In the first study, papaverine had lower mortality compared 
with nimodipine (0% vs. 33%, p<0.05), as well as higher angiographic response (60% vs. 
33%, p<0.01). The second compared colforsin with papaverine, demonstrating lower 
frequency of delayed cerebral infarction when colforsin was used (62% vs. 85%, p=0.039) 
and lower frequency of unfavourable outcome in the colforsin group (34% vs. 66%, 
p=0.032). 
 
The third study randomly compared three different concentrations of papaverine: the 0.4% 
concentration had a higher percentage of neurological improvement compared to the 0.8-
2% concentration (44% vs. 6%, p<0.02), while angiographic improvement was higher in the 
treatment with papaverine at 0.4% compared to the concentrations 0.1-0.2% and 0.8-2% 
(p<0.05); finally, adverse events were more frequent in the group that received papaverine 
with a concentration of 0.8-2% (p<0.005) compared to the concentrations 0.1-0.2% and 
0.4%. The risk of bias was moderate-serious in the non-randomised trials and unclear in 
the randomised trial. 
 
Three studies (125 patients) evaluated the types of balloon angioplasty, the number of 
combination therapy sessions (TBA + IAVI), and stent retriever therapy. The first study 
compared compliant versus non-compliant balloon angioplasty without finding any 
statistically significant associations. The second study compared the number of sessions 
of combined endovascular therapy (TBA + IAVI), 1-2 sessions vs. 3-6 sessions, without 
finding any significant differences. The third study compared different sequences of stent 
therapy; one group received vasodilator before retrievable stent placement and the other 
group received management with a retrievable stent prior to the administration of the 
vasodilator without finding significant differences. The risk of bias was moderate-critical. 
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Finally, the results on the safety of endovascular therapy did not show an increase in 
adverse events in any of the comparison groups, except for the increased risk of 
complications at high concentrations of papaverine compared to lower concentrations.  
 
Adverse events reported in patients receiving intra-arterial vasodilator infusion included 
embolic/spastic vascular occlusion, hemodynamic instability, cardiac arrhythmia, 
endocranial hypertension, and transient focal neurologic deficit.  
 
Lastly, adverse events observed in balloon angioplasty included re-bleeding of the brain 
aneurysm, hardware rupture, and arterial occlusion. No significant differences in this regard 
were found in the comparison groups. 
4.2 Overall completeness and applicability of 
evidence 
Although a comprehensive search was conducted to retrieve all published and unpublished 
studies, this systematic review included studies with moderate-critical risk of bias, thus the 
confidence in the effect estimate is low. In addition, in many cases, data were incomplete, 
and some important clinical outcomes were not reported. For example, most of the included 
studies did not assess long-term functional status, which accounts for the overall impact of 
the intervention, while no studies assessed quality of life or costs associated with care. 
Furthermore, the definition of some outcomes (e.g., angiographic improvement) had great 
variability among studies.  
 
The applicability of the evidence in the target population (patients with cerebral vasospasm 
secondary to aneurysmal subarachnoid haemorrhage) is limited since the studies retrieved 
had substantial degree of heterogeneity in their clinical contexts, case definitions, and 
methodological designs.  
 
The interventions discussed in this review should be implemented with caution in certain 
clinical settings; however, they require trained personnel, local or general anesthesia, 
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appropriate biomedical devices, diagnostic imaging equipment, and infrastructure to enable 
the execution of endovascular therapy. 
4.3 Quality of the evidence 
Non-randomised controlled studies were assessed for risk of bias using the ROBINS-I 
instrument as low (0%), moderate (42%), serious (42%), and critical (16%). The risk of bias 
of the randomised controlled clinical trial was unclear according to the Cochrane 
Collaboration tool. Therefore, confidence in the effect estimation was very low, and the 
actual effect is likely to be substantially different. Confidence is very low due to study 
limitations (lack of control for confounding factors, selection bias, lack of blinding for 
outcome assessment, and risk of bias from selective reporting), and because some 
imprecise results were documented (few patients and events). It was not possible to assess 
the risk of reporting bias as there were very few studies included in each comparison. 
4.4 Potential biases in the review process 
There were concerns about reporting bias, as this was a possibility due to the limited 
number of studies for each comparison. Another major limitation of this systematic review 
is measurement bias, especially in the studies in which the authors evaluated the outcomes 
subjectively. Finally, although a comprehensive search was conducted, not all studies 
reported results for most outcomes of clinical relevance; moreover, the differences reported 
as significant in this review originated from a few studies, with a high number of imprecise 








5. Conclusions  
5.1 Implications for practice 
Due to the risk of bias, imprecision, and heterogeneity of many of the outcomes assessed 
in this review, the positive and negative effects of endovascular therapy compared to 
medical therapy should be considered with caution (Appendix 4). The frequency of adverse 
events was low and did not seem to be different between medical therapy and endovascular 
therapy, with moderate to critical risk of bias. 
 
Evidence from some of the results showing that intra-arterial vasodilator infusion is superior 
to standard treatment, in terms of functional outcome at 3 months and outcome of 
angiographic vasospasm, is at moderate risk of bias.  
 
When comparing the effects of different vasodilators, papaverine seems to be superior to 
nimodipine because it has lower mortality rates and higher angiographic improvement 
rates. Compared to colforsin, papaverine had worse functional outcome at discharge and 
higher frequency of cerebral infarction during follow-up. The quality of evidence from 
studies evaluating multiple vasodilators had a moderate to serious risk of bias. 
 
The comparison of different endovascular therapy options shows no significant difference 
between intra-arterial vasodilator infusion and balloon angioplasty, with moderate to critical 
risk of bias. 
5.2 Implications for research 
High-quality controlled clinical trials regarding treatment are needed for patients with 
cerebral vasospasm secondary to subarachnoid haemorrhage, particularly comparing 
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endovascular therapy to standard treatment. Further research should focus on avoiding risk 
of bias, especially in relation to the allocation and selection of intervention groups, the 
failure to comply with the intention-to-treat principle, and selective reporting. Those studies 
should report major clinical outcomes such as functional outcome in the long-term, adverse 
events, the need for additional interventions, patient satisfaction with the treatment 
















A. Appendix 1: Classification and 
scales 
Glasgow Outcome Scale (GOS) 
 
Unfavourable outcome: categories 1, 2 or 3 (67,68). 
 
Table 5-1: Glasgow Outcome Scale.  
Category Definition 
1. Death Severe injury or death without recovery of 
consciousness 
2. Persistent vegetative state Severe damage with prolonged state of 
unresponsiveness and a lack of higher mental functions 
3. Severe disability Severe injury with permanent need for help with daily 
living 
4. Moderate disability No need for assistance in everyday life, employment is 
possible but may require special equipment 
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Glasgow Outcome Scale Extended (GOS-E) 
 
Unfavourable outcome: categories 1, 2, 3 or 4 (67,68). 
 
Table 5-2: Glasgow Outcome Scale Extended.  
Category Definition 
1. Death  
2. Vegetative state Condition of unawareness with reflex responses only, but 
with periods of spontaneous eye opening 
3. Low severe disability Person who is dependent for daily support for mental or 
physical disability, usually a combination of both. If the 
person cannot be left alone for more than 8 hours at 
home, it is low level of severe disability 
4. Upper severe disability Person who is dependent for daily support for mental or 
physical disability, usually a combination of both. If the 
person can be left alone for more than 8 hours at home, it 
is upper level of severe disability 
5. Low moderate disability Person has some disability such as aphasia, hemiparesis 
or epilepsy and/or deficits of memory or personality but is 
able to look after him/herself. Person is independent at 
home but dependent outside. If unable to return to work, 
even with special arrangements, it is low level of moderate 
disability 
6. Upper moderate disability Person has some disability such as aphasia, hemiparesis 
or epilepsy and/or deficits of memory or personality, but is 
able to look after him/herself. Person is independent at 
home, but dependent outside. If able to return to work with 
special arrangements, it is upper level of moderate 
disability 
7. Low good recovery Resumption of normal life with the capacity to work even 
if pre-injury status has not been achieved. Some people 
have minor neurological or psychological deficits. If these 
deficits are disabling, then it is lower level of good 
recovery 
8. Upper good recovery Resumption of normal life with the capacity to work even 
if pre-injury status has not been achieved. Some people 
have minor neurological or psychological deficits. If these 










Modified Rankin Scale (mRS) 
 
Unfavourable outcome: categories 4, 5 o 6 (69) 
Table 5-3: Modified Rankin Scale.  
Category Definition 
0 No symptoms at all 
1 No significant disability and able to carry out all 
duties 
2 Slight disability. Unable to carry out some previous 
activities but able to look after own affairs without 
assistance 
3 Moderate disability. Requiring some help but able to 
walk without assistance 
4 Moderately severe disability. Unable to walk without 
assistance and unable to attend to own bodily 
needs without assistance 
5 Severe disability. Bedridden, incontinent and 





Assessed with CT (38) 
Table 5-4: Fisher’s Scale.  
Category Definition 
Grade I no subarachnoid (SAH) or intraventricular 
haemorrhage (IVH) detected 
Grade II diffuse thin (<1 mm) SAH, no clots 
Grade III localized clots and/or layers of blood >1 mm in 
thickness, no IVH 
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Hunt & Hess Scale 
 
Assessed at beginning (39). 
Table 5-5: Hunt & Hess Scale.  
Category Definition 
Grade 0 Unruptured aneurysm 
Grade 1 Mild Headache, Alert and Oriented, Minimal (if any) 
Nuchal Rigidity 
Grade 2 Full Nuchal Rigidity, Moderate-Severe Headache, 
Alert and Oriented, No Neuro Deficit (Besides CN 
Palsy) 
Grade 3 Lethargy or Confusion, Mild Focal Neurological 
Deficits 
Grade 4 Stuporous, More Severe Focal Deficit 
Grade 5 Comatose, showing signs of severe neurological 
impairment (ex: posturing) 
 
World Federation of Neurosurgical Societies Scale 
 
Assessed at beginning (39). 
Table 5-6: World Federation of Neurosurgical Societies Scale.  
Category Definition 
Glasgow Coma Scale Motor Deficit 
Grade I 15 points Not 
Grade II 13-14 points Not 
Grade III 13-14 points Yes 
Grade IV 7-12 points Yes / Not 











B. Appendix 2: Search strategy 
MEDLINE (R) <1946 to April Week 4 2020> 
1     exp subarachnoid hemorrhage/ (21096) 
2     ((subarachnoid$ or arachnoidal$) adj3 (h?emorrhag$ or h?ematoma or bleed$ or 
blood)).tw. (22733) 
3     1 or 2 (28017) 
4     vasospasm, intracranial/ (3187) 
5     (((brain or cerebr$ or intracranial) adj3 spasm) or vasospasm or angiospasm or 
vasoconstriction).tw. (35169) 
6     4 or 5 (35586) 
7     3 and 6 (5629) 
8     endovascular procedures/ (18125) 
9     vascular surgical procedures/ (30901) 
10     ((((blood adj3 vessel) or vascular) adj3 (repair or reconstruct$ or surg$)) or 
angiosurgery).tw. (20252) 
11     (endovasc$ adj3 (procedure or surg$ or treatment$ or repair)).tw. (23548) 
12     angioplasty/ or angioplasty, balloon/ or stents/ or dilatation/ (92556) 
13     (((balloon or transluminal) adj3 angioplasty) or (artery adj3 dilatation) or stent$ or 
dilat$).tw. (217849) 
14     exp vasodilator agents/ or exp phosphodiesterase inhibitors/ or dantrolene/ (457814) 
15     (vasodilat$ or (vasoactive adj3 antagon$) or vasorelaxant$ or IAVI).tw. (64752) 
16     (calcium adj3 (inhib$ or antagon$ or block$)).tw. (42814) 
17     (acetylcholine or adenosine or adrenomedullin or alprostadil or amiodarone or 
amlodipine or amrinone or bencyclane or bepridil or betahistine or bradykinin or carvedilol 
or celiprolol or chromonar or cilostazol or colforsin or cromakalim or cyclandelate or 
dantrolene or diazoxide or dihydroergocristine or dihydroergocryptine or dilazep or 
diltiazem or dipyridamole or dyphylline or enoximone or ergoloid mesylates or erythritol or 
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erythrityl tetranitrate or fasudil or felodipine or fenoldopam or flunarizine or hexobendine or 
hydralazine or iloprost or isosorbide dinitrate or isoxsuprine or isradipine or kallidin or khellin 
or lidoflazine or mibefradil or milrinone or minoxidil or molsidomine or moxisylyte or nafronyl 
or nebivolol or niacin or nicardipine or nicergoline or nicorandil or nifedipine or nimodipine 
or nisoldipine or nitrendipine or nitroglycerin or nitroprusside or nonachlazine or nylidrin or 
oxprenolol or oxyfedrine or papaverine or pentaerythritol tetranitrate or pentoxifylline or 
perhexiline or phenoxybenzamine or pinacidil or pindolol or polymethyl methacrylate or 
prenylamine or propranolol or sildenafil citrate or simendan or sodium azide or suloctidil or 
tadalafil or theobromine or theophylline or thiouracil or tolazoline or trapidil or trimetazidine 
or vardenafil dihydrochloride or verapamil or vincamine or xanthinol niacinate).tw. (369118) 
18     or/8-17 (942566) 
19     7 and 18 (1911) 
20     exp subarachnoid hemorrhage/dt [Drug Therapy] (1403) 
21     brain vasospasm/dt [Drug Therapy] (0) 
22     20 or 21 (1403) 
23     19 or 22 (3003) 
24     randomized controlled trial.pt. (504191) 
25     controlled clinical trial.pt. (93615) 
26     randomized.ab. (411665) 
27     placebo.ab. (187040) 
28     randomly.ab. (282000) 
29     trial.ab. (430105) 
30     groups.ab. (1745117) 
31     or/24-30 (2543514) 
32     23 and 31 (832) 
 
Embase  
No.  Query Results                                                 Results  Date        
#35. #23 AND #34                                                    1,070  2 May 2020  
#34. #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR        2,424,089  2 May 2020  
     #31 OR #32 OR #33 
#33. assign*:ab,ti OR allocat*:ab,ti                           532,031  2 May 2020  
#32. trial:ti                                                   302,767  2 May 2020  
#31. placebo*:ab,ti OR sham:ab,ti                             419,690  2 May 2020  
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#30. (cross-over:ab,ti OR cross:ab,ti) AND over:ab,ti         205,644  2 May 2020  
     OR crossover:ab,ti 
#29. ((singl* OR doubl* OR tripl* OR trebl*) NEAR/5           241,866  2 May 2020  
     (blind* OR mask*)):ab,ti 
#28. random*:ab,ti OR rct:ab,ti OR rcts:ab,ti               1,532,344  2 May 2020  
#27. 'single blind procedure'/de OR 'triple blind              38,794  2 May 2020  
     procedure'/de 
#26. 'double blind procedure'/de                             171,671  2 May 2020  
#25. 'crossover procedure'/de                                   62,681  2 May 2020  
#24. 'randomized controlled trial'/de OR 'randomized          773,780  2 May 2020  
     controlled trial (topic)'/de 
#23. #19 OR #22                                                  5,846  2 May 2020  
#22. #20 OR #21                                                  3,608  2 May 2020  
#21. 'brain vasospasm'/dd_dt                                     1,715  2 May 2020  
#20. 'subarachnoid hemorrhage'/exp/dd_dt                        2,220  2 May 2020  
#19. #7 AND #18                                                  3,528  2 May 2020  
#18. #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR      1,280,987  2 May 2020  
     #15 OR #16 OR #17 
#17. ((acetylcholine:ab,ti OR adenosine:ab,ti OR              106,057  2 May 2020  
     adrenomedullin:ab,ti OR alprostadil:ab,ti OR amiodarone:ab,ti OR amlodipine:ab,ti OR  
     amrinone:ab,ti OR bencyclane:ab,ti OR bepridil:ab,ti OR betahistine:ab,ti OR  
     bradykinin:ab,ti OR carvedilol:ab,ti OR celiprolol:ab,ti OR chromonar:ab,ti OR  
     cilostazol:ab,ti OR colforsin:ab,ti OR cromakalim:ab,ti OR cyclandelate:ab,ti OR  
     dantrolene:ab,ti OR diazoxide:ab,ti OR dihydroergocristine:ab,ti OR  
     dihydroergocryptine:ab,ti OR dilazep:ab,ti OR diltiazem:ab,ti OR dipyridamole:ab,ti OR  
     dyphylline:ab,ti OR enoximone:ab,ti OR ergoloid:ab,ti) AND mesylates:ab,ti OR  
     erythritol:ab,ti OR (erythrityl:ab,ti AND tetranitrate:ab,ti) OR fasudil:ab,ti OR  
     felodipine:ab,ti OR fenoldopam:ab,ti OR flunarizine:ab,ti OR hexobendine:ab,ti OR  
     hydralazine:ab,ti OR iloprost:ab,ti OR (isosorbide:ab,ti AND dinitrate:ab,ti) OR  
     isoxsuprine:ab,ti OR isradipine:ab,ti OR kallidin:ab,ti OR khellin:ab,ti OR  
     lidoflazine:ab,ti OR mibefradil:ab,ti OR milrinone:ab,ti OR minoxidil:ab,ti OR  
     molsidomine:ab,ti OR moxisylyte:ab,ti OR nafronyl:ab,ti OR nebivolol:ab,ti  
     OR niacin:ab,ti OR nicardipine:ab,ti OR nicergoline:ab,ti OR nicorandil:ab,ti  
     OR nifedipine:ab,ti OR nimodipine:ab,ti OR nisoldipine:ab,ti OR nitrendipine:ab,ti  
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     OR nitroglycerin:ab,ti OR nitroprusside:ab,ti OR nonachlazine:ab,ti OR nylidrin:ab,ti  
     OR oxprenolol:ab,ti OR oxyfedrine:ab,ti OR papaverine:ab,ti OR  
     (pentaerythritol:ab,ti AND tetranitrate:ab,ti) OR pentoxifylline:ab,ti OR  
     perhexiline:ab,ti OR phenoxybenzamine:ab,ti OR pinacidil:ab,ti OR pindolol:ab,ti  
     OR polymethyl:ab,ti) AND methacrylate:ab,ti OR prenylamine:ab,ti OR  
     propranolol:ab,ti OR (sildenafil:ab,ti AND citrate:ab,ti) OR simendan:ab,ti  
     OR (sodium:ab,ti AND azide:ab,ti) OR suloctidil:ab,ti OR tadalafil:ab,ti  
     OR theobromine:ab,ti OR theophylline:ab,ti OR thiouracil:ab,ti OR tolazoline:ab,ti  
     OR trapidil:ab,ti OR trimetazidine:ab,ti OR (vardenafil:ab,ti AND  
     dihydrochloride:ab,ti) OR verapamil:ab,ti OR vincamine:ab,ti OR (xanthinol:ab,ti  
     AND niacinate:ab,ti) 
#16. (calcium NEAR/3 (inhib* OR antagon* OR                   57,277  2 May 2020  
     block*)):ab,ti 
#15. vasodilat*:ab,ti OR ((vasoactive NEAR/3                   90,384  2 May 2020  
     antagon*):ab,ti) OR vasorelaxant*:ab,ti OR  
     iavi:ab,ti 
#14. 'vasodilator agent'/exp OR 'phosphodiesterase            672,712  2 May 2020  
     inhibitor'/exp OR 'dantrolene'/de 
#13. (((balloon OR transluminal) NEAR/3                       380,471  2 May 2020  
     angioplasty):ab,ti) OR ((artery NEAR/3  
     dilatation):ab,ti) OR stent*:ab,ti OR  
     dilat*:ab,ti 
#12. 'angioplasty'/de OR 'percutaneous transluminal           144,562  2 May 2020  
     angioplasty'/de OR 'stent'/de OR 'dilatation'/de 
#11. (endovasc* NEAR/3 (procedure OR surg* OR                 41,300  2 May 2020  
     treatment* OR repair)):ab,ti 
#10. ((blood OR vessel OR vascular) NEAR/3 (repair OR         57,211  2 May 2020  
     reconstruct* OR surg*)):ab,ti 
#9.  'vascular surgery'/de OR angiosurgery:ab,ti               38,468  2 May 2020  
#8.  'endovascular surgery'/de                                  24,569  2 May 2020  
#7.  #3 AND #6                                                   9,170  2 May 2020  
#6.  #4 OR #5                                                   50,537  2 May 2020  
#5.  (((brain OR cerebr* OR intracranial) NEAR/3               48,579  2 May 2020  
     spasm):ab,ti) OR vasospasm:ab,ti OR  
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     angiospasm:ab,ti OR vasoconstriction:ab,ti 
#4.  'brain vasospasm'/de                                        7,168  2 May 2020  
#3.  #1 OR #2                                                   48,960  2 May 2020  
#2.  ((subarachnoid* OR arachnoidal*) NEAR/3                   34,493  2 May 2020  
     (h$emorrhag* OR h$ematoma OR bleed* OR  
     blood)):ab,ti 





C. Appendix 3: Characteristics of studies 













events Exposure Control Sample Bias 
Aburto 2012 x  x x     TAB IAV 30 Serious 
Andereggen 
2017 x  x x    x 
IAV + 
TAB # 
IAV + TAB 
# 83 Critical 
Bele 2015 x x x x    x IAV MED 41 Moderate 
Besheli 
2017  x x x     IAV MED 115 Serious 
Coenen 
1998     x    IAV TAB 69 Moderate 
Crespy 2018 x  x     x IAV MED 101 Serious 
Elayoubi 
2013      x   IAV MED 18 Serious 
Elliott 1998  x x   x  x IAV TAB 52 Critical 
Elsayed 
2006         IAV TAB 22 - 
Frontera 
2011  x    x   IAV IAV + TAB 92 Critical 
Goel 2016 x x   x    IAV MED 53 Serious 
Hosmann 
2018    x  x   IAV IAV + TAB 77 Serious 
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Katoh 1999  x x  x   x TAB / IAV MED 72 Moderate 
Kerz 2012  x x x  x x  IAV IAV 30 Serious 
Kerz 2016        x IAV IAV + TAB 47 Moderate 
Khatri 2011  x x    x  
IAV + 
TAB MED 146 Moderate 
Kwon 2018  x x  x x  x 
IAV + 
Stent Stent + IAV 12 Moderate 
Miley 2011  x  x    x TABc TABnc 30 Serious 
Mortimer 
2014 x x x    x x 
IAV + 
TAB MED 80 Critical 
Nakamura 
2013  x x x    x IAV MED 31 Serious 
Oskouian 
2002  x   x    IAV 
TAB / IAV 
+TAB 45 Serious 
Polin 1998 x   x     IAV MED 93 Moderate 
Polin 2000 x        
IAV + 
TAB MED 121 Moderate 
Sokolowski 
2017  x    x   TAB 
IAV + TAB 
/ IAV 159 Moderate 
Suzuki 2012  x x x    x IAV IAV 133 Moderate 
Sawada 
2012     x x  x IAV IAV 31 Unclear 
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Table 5-8: Risk of bias in non-randomised studies.  
Study D1 D2 D3 D4 D5 D6 D7 Overall 
Aburto 2012 Serious Low Moderate Low Low Low Low Serious 
Andereggen 2017 Critical Moderate Low Low Low Low Moderate Critical 
Bele 2015 Moderate Moderate Low Low Low Low Moderate Moderate 
Besheli 2017 Serious Moderate Moderate Low Low Low Low Serious 
Coenen 1998 Moderate Low Low Low Low Low Low Moderate 
Crespy 2018 Serious Low Low Low Serious Low Moderate Serious 
Elayoubi 2013 Serious No information No information No information No information Low Moderate Serious 
Elliott 1998 Serious Low Low Critical Low Moderate Moderate Critical 
Frontera 2011 Critical Critical Serious Serious Low Low Moderate Critical 
Goel 2016 Serious Low Serious Low Low Moderate Moderate Serious 
Hosmann 2018 Serious Low Low Serious Moderate Low Moderate Serious 
Katoh 1999 Moderate Low Low Low Low Low Moderate Moderate 
Kerz 2012 Serious Low Low Low Low Serious Moderate Serious 
Kerz 2016 Moderate Low Low Low Low Moderate Moderate Moderate 
Khatri 2011 Moderate Low Low Low Low Moderate Moderate Moderate 
Kwon 2018 Serious Low Low Low Low Moderate Moderate Moderate 
Miley 2011 Serious Low Low Low Low Low Moderate Serious 
Mortimer 2014 Critical Low Low Low Low Low Moderate Critical 
Nakamura 2013 Serious Low Moderate Low Low Moderate Moderate Serious 
Oskouian 2002 Serious Low Low Low Low Low Moderate Serious 
Polin 1998 Moderate Low Low Low Low Low Low Moderate 
Polin 2000 Moderate Low Low Low Low Low Low Moderate 
Sokolowski 2017 Moderate Low Low Low Low Moderate Moderate Moderate 




Tabla 5-9: Description of interventions.  
Study Description of the intervention Description of the comparator 
Aburto 2012 Nimodipine diluted in saline (solution up to 0.200 mg), dose 1200 mg Compliant balloon, no anticoagulation 
Andereggen 
2017 
1-2 Sessions Nimodipine 2.5 mg per blood vessel. Balloon does not specify 
type or anticoagulation 
3-6 sessions Nimodipine 2.5 mg per vessel, balloon: does not specify type or 
anticoagulation 
Bele 2015 
Continuous infusion Nimodipine 0.5-1.2 mg / h + heparin, according to 
response by multimodal therapy + Triple H therapy Triple H therapy according to response by DTC, PBTO2, CBF 
Besheli 2017 Nicardipine 1-15mg +- Milrinone 5-15mg Triple H Therapy + Oral Nimodipine 
Coenen 
1998 
Intra-arterial papaverine, does not refer dose, was administered 15 hours 
after symptoms 
Balloon angioplasty at 21 hours after symptoms, does not refer if anticoagulated or the 
type of balloon 
Crespy 2018 
Milrinone IA 8-24 mg + Milrinone 1 mcg / kg / min 14 days + Mechanical 
angioplasty if two IAVI options fail 
Milrinone 1 mcg / kg / min + - boluses 8 mg 7 Days + - angioplasty or IAVI according 
to clinical criteria 
Elayoubi 
2013 Milrinone IA + - balloon angioplasty Patient with or without vasospasm who did not receive milrinone 
Elliott 1998 IA Papaverine 300 mg per blood vessel, no anticoagulation Low pressure angioplasty balloon, anticoagulation 
Frontera 
2011 Silica Commodore Balloon Posterior to IAVI 
Papaverine (13 ptes) 75 mg initial dose max 300 mg per territory; Verapamil (46 ptes) 
initial dose 5 mg max 30 mg per vascular territory 
Goel 2016 Nimodipine IA 1-3 mg max 6 mg Oral nimodipine + PAS 150-150 
Hosmann 
2018 Papaverine IA, mean dose 252 +- 191 mg 
Papaverine + TBA, does not specify the type of balloon, they only used this therapy in 
case of severe vasospasm 
Katoh 1999 Papaverine IA 40-160 mg Hypertensive hypervolemic hemodilution 
Katoh 1999 Silicone Balloon Hypertensive hypervolemic hemodilution 
Katoh 1999 Papaverine IA 40-160 mg Silicone balloon 
Kerz 2012 Papaverine IA 300-600 mg Nimodipine IA 1-1.5mg 
Kerz 2016 Nimodipine IA 1.5 mg per territory, 2.5 mg dose per patient Balloon that does not over-inflate 
Khatri 2011 
Compliant / non-compliant balloon angioplasty + - vasodilator (nicardipine, 
verapamil, magnesium sulfate) Hypervolemic hypertension 
Kwon 2018 Nicardipine IA 2-3 mg, followed by Stent Retriever, with heparin Stent Retriever, followed by Nicardipine IA 2-3 mg, with heparin 
Miley 2011 Compliant balloon, heparin Non-compliant balloon, heparin 
Mortimer 
2014 Compliant balloon, heparin or IAVI (Verapamil 10-15 mg or Papaverine) Nimodipine IV 20 mcg / kg / h, PAS 140-160, hydration 
Nakamura 
2013 Fasudil 30mg, 3mg / min selective Fasudil IV + Edarabon IV 
Oskouian 
2002 Papaverine IA 0.3% 60-360 mg Low pressure compliant balloon 
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Polin 1998 Papaverine 90mg / 100mL up to 300mg / 100ml Same dose of tirilizad + nimodipine 60 mg oral 
Polin 2000 Balloon angioplasty + - IAVI papaverine Same dose of tirilizad + nimodipine 60 mg oral 
Sokolowski 
2017 IA Papaverine Verapamil  Angioplasty + heparin 
Sokolowski 
2017 Angioplasty + heparin Combined endovascular therapy 







Table 5-10: Description of outcomes.  
Study Outcome Description 
Aburto 2012 Long term unfavourable 1 year. 
Aburto 2012 Long term unfavourable 3 moths. 
Aburto 2012 Mortality 1 year. 
Aburto 2012 Cerebral ifarction Doesn´t specify time of infarction assessment, nor the evaluators, nor the blinding. 
Andereggen 2017 Long term unfavourable Last follow up 11 +- 6.3, range 2-22 months, mRS 3-6. 
Andereggen 2017 Mortality Last follow up 11 +- 6.3, range 2-22 months, mRS 6. 
Andereggen 2017 Cerebral ifarction At discharge, doesn´t specify who assessed, nor blinding. 
Andereggen 2017 Adverse events 
Related to procedures, arterial dissections: 1 event in the intervention group and 5 in the control group (1 nneded stent), 1 
event of pseudoaneurysm in the puncture site. 
Bele 2015 Long term unfavourable GOS at 6 months. 
Bele 2015 
 
Short term unfavourable  At discharge, GOS (unfavourable was defined as 1-3). 
Bele 2015 Mortality 6 months. 
Bele 2015 Cerebral ifarction CT at discharge, independent neuroradiologist . 
Bele 2015 Adverse events 
Related with the procedura, 1 case of vascular oclusion (revascularization), 1 embolic/sastic oclusion, general complications 
as pneumonia or heart failure. No cases of sepsia, no bleeding related with heparin. 
Besheli 2017 Short term unfavourable  Median of GOS score. 
Besheli 2017 Mortality During hospital stay. 
Besheli 2017 Cerebral ifarction During hospital stay. 
Coenen 1998 
Neurological deficit 
improvement Assessment by using mGCS at day 1 and 4, doesn’t specify whether it was blind or independent. 
Crespy 2018 Long term unfavourable mRS at 1 year – phone call with patient, family or physician. 
Crespy 2018 Mortality Aparently at 1 year. 
Crespy 2018 Adverse events Included: vasopresor treatment, cardiac arritmia, hypokalemia, hemodinamic instability, cardiac schock. 
Elayoubi 2013 
Angiographic vasospasm 
improvement 8 radiologist assessed arterial diameter by all the evaluators. 
Elliott 1998 Short term unfavourable Unfavourable = severely disabled, vegetative, or dead. 
Elliott 1998 
Angiographic vasospasm 
improvement At the time of initial treatment. 
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Elliott 1998 Adverse events Re-bleeding. 
Frontera 2011 Short term unfavourable 
Hospital discharge disposition was dichotomized as poor (expired, discharged to a nursing home or subacute care facility) vs. 
good (discharged to home, an acute rehabilitation facility, or home with a health aide). 
Goel 2016 Long term unfavourable 
GOS and modified Rankin Scale at discharge and at 3 months. The outcome was divided into two groups: favourable (GOS 
4–5, modified Rankin scale 0–3) and unfavourable (GOS 1–3, modified Rankin scale 4–5). 
Goel 2016 Short term unfavourable 
GOS and modified Rankin Scale at discharge and at 3 months. The outcome was divided into two groups: favourable (GOS 
4–5, modified Rankin scale 0–3) and unfavourable (GOS 1–3, modified Rankin scale 4–5). 
Goel 2016 
Neurological deficit 
improvement The clinical status was assessed every few hours in either group. 
Hosmann 2018 Cerebral ifarction CT at 10 days post-treatment, blind evaluators, by vascular territories. 
Hosmann 2018 
Angiographic vasospasm 
improvement Positive if blood vessel dilatation by territory, when improved more than one category 
Katoh 1999 Short term unfavourable Glasgow Outcome Scale 
Katoh 1999 Short term unfavourable Glasgow Outcome Scale 
Katoh 1999 Adverse events 
Serious and transitory adverse events: in the case of papaverine were altered state of consciousness 36%, blood pressure 
elevation 14%, decerebration posture 7%, conjugate gaze deviation 7%, tachycardia 7%, sweating 7%, nausea 7% 
Katoh 1999 Short term unfavourable Glasgow Outcome Scale 
Kerz 2012 Short term unfavourable Glasgow Outcome Scale 
Kerz 2012 Mortality During hospital stay 
Kerz 2012 Cerebral ifarction CT 4-14 days posterior of bleeding, two blind assessors 
Kerz 2012 
Angiographic vasospasm 
improvement Assessment of six main blood vessels, improvement for each vessel 
Kerz 2016 Adverse events Arterial oclusion, arterial disection, cerebral infarction 
Khatri 2011 Short term unfavourable at discharge, mRS, one blind assessor 
Khatri 2011 Mortality 1 year follow up 
Kwon 2018 Short term unfavourable mRS at discharge 
Kwon 2018 
Neurological deficit 
improvement Doesn’t specify 
Kwon 2018 
Angiographic vasospasm 
improvement DSA at 24 hours, doesn’t specify if blind or independent 
Kwon 2018 Adverse events None of the complicated caused a permanent deficit. Complications included blood vessel rupture or oclusion. 
Miley 2011 Cerebral ifarction CT, one blind assessor. 
Miley 2011 Short term unfavourable Discharge, mRS. 
Miley 2011 Mortality Any cause mortality. 
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Miley 2011 Adverse events Blood vessel rupture, arterial dissection. 
Mortimer 2014 Long term unfavourable GOS, mRS, blind independent assessors, at 3 months. 
Mortimer 2014 Short term unfavourable GOS, mRS, blind independent assessors. 
Mortimer 2014 Adverse events Thrombo-embolic event. 
Nakamura 2013 Short term unfavourable Glasgow Outcome Scale. 
Nakamura 2013 Cerebral ifarction CT. 
Nakamura 2013 Adverse events Seizures. 
Nakamura 2013 Short term unfavourable Glasgow Outcome Scale. 
Nakamura 2013 Cerebral ifarction CT. 
Nakamura 2013 Adverse events Seizures. 
Oskouian 2002 Short term unfavourable Glasgow Outcome Scale. 
Oskouian 2002 Short term unfavourable Glasgow Outcome Scale. 
Oskouian 2002 Short term unfavourable Glasgow Outcome Scale. 
Polin 1998 Long term unfavourable GOS at 3 months, one blind assessors.  
Polin 1998 Cerebral ifarction CT , blind evaluators.  
Polin 2000 Long term unfavourable GOS at 3 moths, blind assessors.  
Sokolowski 2017 Short term unfavourable mRS at discharge, poor outcome was defined as 3-6. 
Sokolowski 2017 
Angiographic vasospasm 
improvement Reperfusion was defined as narrowing improvement over 50% of stenosis. 
Sokolowski 2017 Short term unfavourable mRS at discharge, poor outcome was defined as 3-6. 
Sokolowski 2017 
Angiographic vasospasm 
improvement Reperfusion was defined as narrowing improvement over 50% of stenosis. 
Sokolowski 2017 Short term unfavourable mRS at discharge, poor outcome was defined as 3-6. 
Sokolowski 2017 
Angiographic vasospasm 
improvement Reperfusion was defined as narrowing improvement over 50% of stenosis. 
Suzuki 2012 Short term unfavourable mRS at discharge. 
Suzuki 2012 Cerebral ifarction MRI. 
Suzuki 2012 Mortality At discharge. 
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Tabla 5-11: Effect of interventions.  










DM Value CI Inf CI Sup Author’s report 
Aburto 2012 
Long term 
unfavourable IAVI Nimodipine TAB  22 8 5 3 0,64 OR 0,49 0,06 4,38  
Aburto 2012 
Long term 
unfavourable IAVI Nimodipine TAB  22 8 10 4 1,00 OR 0,83 0,12 5,79  
Aburto 2012 Mortality IAVI Nimodipine TAB  22 8 3 3 0,30 OR 0,26 0,03 2,71  
Aburto 2012 
Cerebral 




unfavourable IAVI+TAB 1-2 Sesions IAVI+TAB 3-6 sesions 52 31 21 13 1,00 OR 0,94 0,35 2,56  
Andereggen 




ifarction IAVI+TAB 1-2 Sesions IAVI+TAB 3-6 sesions 49 31 18 17 0,16 OR 0,48 0,17 1,31 
OR 1.28 IC 95% 
(0.66–2.46) P=.469 
Andereggen 
2017 Adverse events IAVI+TAB 1-2 Sesions IAVI+TAB 3-6 sesions 51 31 1 5 0,03 OR 0,10 0,00 1,01  
Bele 2015 
Long term 
unfavourable IAVI Nimodipine Medical  21 20 5 15 0,00 OR 0,10 0,02 0,52  
Bele 2015 
Short term 
unfavourable IAVI Nimodipine Medical  21 20 16 18 0,41 OR 0,36 0,03 2,61  
Bele 2015 Mortality IAVI Nimodipine Medical  21 20 2 7 0,05 OR 0,20 0,02 1,30  
Bele 2015 
Cerebral 
ifarction IAVI Nimodipine Medical  21 20 9 15 0,04 OR 0,25 0,07 0,95  






+- Milrinone Medical  22 93 
mean 
2,6 mean 1 0,00 DM 1,60 na na P<0.001 
Besheli 
2017 Mortality IAVI 
Nicardipine 






+- Milrinone Medical  22 93 2 0 0,04 OR 22,80 1,05 493,11  
Besheli 
2017 ICU stay IAVI 
Nicardipine 









unfavourable IAVI Milrinone Medical  24 77 8 18 0,42 OR 1,64 0,60 4,45  
Crespy 









improvement IAVI Milrinone Medical  72 72 65 8 0,00 OR 74,29 25,44 216,89  
Elliott 1998 
Short term 
unfavourable IAVI Papaverine TAB  13 39 5 13 0,75 OR 1,25 0,34 4,59  




improvement IAVI Papaverine TAB  13 39 13 39 1,00 OR 1,00 na na  




unfavourable IAVI + TAB  IAVI Papaverine 33 59    OR    
OR 0.6, 95% CI 





improvement IAVI + TAB  IAVI Papaverine 33 59 33 52 0,05 OR 9,57 0,53 173,14  
Goel 2016 
Long term 
unfavourable IAVI Nimodipine Medical  36 13 13 6 0,53 OR 0,66 0,18 2,38  
Goel 2016 
Short term 












angiográfica IAVI Papaverine IAVI+TAB  63 14 19 7 0,21 OR 0,43 0,13 1,40  
Katoh 1999 
Short term 
unfavourable IAVI Papaverine Medical  4 40 4 19 0,11 OR 9,92 0,50 196,41  
Katoh 1999 Mortality IAVI Papaverine Medical  4 40 1 5 0,46 OR 2,33 0,20 27,03  
Katoh 1999 
Short term 
unfavourable TAB  Medical  12 40 6 19 1,00 OR 1,11 0,30 4,02  




improvement IAVI Papaverine TAB  4 12 1 7 0,57 OR 0,24 0,02 3,01  
Katoh 1999 Adverse events IAVI Papaverine TAB  4 12 0 0 1,00 OR 1,00 na na  
Katoh 1999 
Short term 
unfavourable IAVI Papaverine TAB  4 12 4 6 0,23 OR 9,00 0,40 203,30  
Katoh 1999 Mortality IAVI Papaverine TAB  4 12 1 0 0,25 OR 10,71 0,35 325,25  




unfavourable IAVI Papaverine IAVI Nimodipine 15 15 7 5 0,71 OR 1,75 0,40 7,66  
Kerz 2012 Mortality IAVI Papaverine IAVI Nimodipine 15 15 0 5 0,04 OR 0,10 0,01 0,,65  
Kerz 2012 
Cerebral 




improvement IAVI Papaverine IAVI Nimodipine 138 210 83 69 0,00 OR 3,22 2,09 4,94  




11  DM 2,10 -6,60 10,80  
Kerz 2016 Adverse events IAVI Nimodipine IAVI+TAB  26 21 0 4 0,03 OR 0,09 0,01 0,70  
Khatri 2011 
Short term 
unfavourable IAVI + TAB  Medical  57 89 19 40 0,17 OR  0,62 0,32 1,22 
OR 0,61 IC 95% 
0,27-1,39 
Khatri 2011 Mortality IAVI + TAB  Medical  57 89 13 28 0,35 OR 0,65 0,31 1,37 
OR 0,63 IC 95% 
0,25-1,55 
Khatri 2011 Hospital stay IAVI + TAB  Medical  57 89 15 17 na na na na na P=0,32 
Kwon 2018 
Short term 
unfavourable IAVI + Stent Nicardipine 
Stent + 
IAVI Nicardipine 5 7 2 2 1,00 OR 1,60 0,16 16,48  
Kwon 2018 Mortality IAVI + Stent Nicardipine 
Stent + 




improvement IAVI + Stent Nicardipine 
Stent + 
IAVI Nicardipine 5 7 3 6 0,52 OR 0,28 0,02 3,60  
Kwon 2018 
Mejoría 
angiográfica IAVI + Stent Nicardipine 
Stent + 
IAVI Nicardipine 14 39 10 32 0,45 OR 0,53 0,12 2,36  
Kwon 2018 Adverse events IAVI + Stent Nicardipine 
Stent + 
IAVI Nicardipine 5 7 1 2 1,00 OR 0,66 0,05 8,32  
Miley 2011 
Cerebral 
ifarction TAB  TAB  34 51 7 5 0,21 OR 2,41 0,70 8,31 




unfavourable TAB  TAB  10 20 6 5 0,11 OR 4,29 0,91 20,20  
Miley 2011 Mortality TAB  TAB  10 20 2 4 1,00 OR 1,00 0,15 6,46  








unfavourable IAVI + TAB  Medical  17 63 9 28 0,59 OR 1,40 0,48 4,08  
Mortimer 
2014 Mortality IAVI + TAB  Medical  17 63 0 2 1,00 OR 0,28 0,01 8,36  
Mortimer 












2,4 na DM 7,90 6,49 9,31 P<0.0001 
Mortimer 




unfavourable IAVI Fasudil Medical  10 11 5 8 0,39 OR 0,40 0,07 2,23  
Nakamura 




ifarction IAVI Fasudil Medical  10 10 6 8 0,63 OR 0,40 0,06 2,61  
Nakamura 




unfavourable IAVI Fasudil Medical  9 11 7 8 1,00 OR 1,29 0,18 9,38  
Nakamura 




ifarction IAVI Fasudil Medical  10 10 6 8 0,63 OR 0,40 0,06 2,61  
Nakamura 




























improvement TAB  IAVI+TAB  12 13 6 8 0,70 OR 0,64 0,14 3,00  
Polin 1998 
Long term 
unfavourable IAVI Papaverine Medical  31 62 17 27 0,38 OR 1,57 0,66 3,69  
Polin 1998 
Cerebral 
ifarction IAVI Papaverine Medical  20 54 17 41 0,53 OR 1,70 0,49 5,85  
Polin 2000 
Long term 






Verapamil TAB  100 11 85 8 0,38 OR 2,45 0,46 13,15 P=0.429 






























unfavourable IAVI Papaverine IAVI Colforsin 27 29 18 10 0,03 OR 3,54 1,25 10,01 
P=0.032 Good 
functional outcome 
Colforsin vs PPV 





ifarction IAVI Papaverine IAVI Colforsin 27 29 23 18 0,05 OR 3,18 0,98 10,29 P=0.039 
Suzuki 
2012 Adverse events IAVI Papaverine IAVI Colforsin 27 29 0 0 na na na na na  
Suzuki 










D. Appendix 4: Summary of findings table (GRADE) 
 
Question: endovascular treatment compared to standard management for cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage.  
Comparison: endovascular treatment versus standard management.  
Bibliography: (42,44,62,47,49,50,53,54,58,60,61). 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 









Long term unfavorable outcome (follow up: range 3 months to 12 months; assessed with: GOS, mRS) 
6  observational 
studies  
very serious  serious  not serious  serious  
 
62/167 (37.1%)  110/318 (34.6%)  not estimable  
 
-  CRITICAL  
Mortality 
7  observational 
studies  
very serious  serious  not serious  serious  
 
24/176 (13.6%)  50/393 (12.7%)  not estimable  
 
-  CRITICAL  
Short term unfavorable outcome (at discharge; assessed with: GOS, mRS) 
6  observational 
studies  
very serious  serious  not serious  serious  
 
94/169 (55.6%)  123/237 (51.9%)  not estimable  
 
-  CRITICAL  
Cerebral infarction on brain imaging (delayed) 
4  observational 
studies  
serious  serious  not serious  serious  
 
40/83 (48.2%)  64/177 (36.2%)  not estimable  
 
-  CRITICAL  
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 










4  observational 
studies  
very serious  not serious  not serious  very serious  
 
19/82 (23.2%)  35/171 (20.5%)  not estimable  
 
-  CRITICAL  
Angiographic improvement 
1  observational 
studies  
serious  not serious  not serious  not serious  
 
65/72 (90.3%)  8/72 (11.1%)  not estimable  
 
-  CRITICAL 
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